[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 209
6. Arista-Nasr J, Gómez-Bustamante D, Aguilar-Magaña FA, Saqui-Salces M, Martínez-Benítez B: [Histological findings in 100 needle prostatic biopsies and original diagnosis of benignity]. Rev Invest Clin; 2006 Mar-Apr;58(2):88-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Histological findings in 100 needle prostatic biopsies and original diagnosis of benignity].
  • INTRODUCTION: Detailed revision of prostate biopsies with benign alterations may show potentially malignant lesions limited to isolated fields, which may be overviewed in routine analysis.
  • AIM: To exam the morphological alterations in patients with suspicious of prostatic carcinoma and benign diagnosis in needle biopsies.
  • MATERIALS AND METHODS: During 2000-2001, one hundred consecutive patients with first prostate biopsy diagnosed as benign were included.
  • In this group, there were five biopsies with atypical small acinar proliferation, three with few isolated glands with xanthomatous cytoplasm, and one with scarce atypical cells in the prostatic stroma.
  • Some lesions that simulate carcinoma, as atypical basal cell hyperplasia, post-atrophic hyperplasia, and adenosis were diagnosed as benign, and there was none false positive result.
  • CONCLUSIONS: A small but significant group of the biopsies originally diagnosed as benign lesions, showed atypical lesions in isolated fields that were overlooked in the routine analysis.
  • It is necessary the urologist to ask for a directed review of the biopsies if clinical and laboratory data strongly suggest prostatic carcinoma.
  • [MeSH-major] Prostate / pathology. Prostatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16827260.001).
  • [ISSN] 0034-8376
  • [Journal-full-title] Revista de investigación clínica; organo del Hospital de Enfermedades de la Nutrición
  • [ISO-abbreviation] Rev. Invest. Clin.
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Mexico
  •  go-up   go-down


7. Wolters T, van der Kwast TH, Vissers CJ, Bangma CH, Roobol M, Schröder FH, van Leenders GJ: False-negative prostate needle biopsies: frequency, histopathologic features, and follow-up. Am J Surg Pathol; 2010 Jan;34(1):35-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] False-negative prostate needle biopsies: frequency, histopathologic features, and follow-up.
  • Little is known about the frequency, histopathologic characteristics, and clinical consequences of false-negative prostate biopsies, that is, biopsies classified as benign but containing adenocarcinoma or atypical suspicious glands [atypical small acinar proliferations (ASAP)].
  • Objective of this study was to evaluate false-negative prostate biopsy in a prostate cancer screening setting.
  • Prostate biopsy sets of 196 participants of a screening trial, which had been reported as "benign" at initial diagnosis, followed by a diagnosis of adenocarcinoma in a subsequent screening round were reviewed by 2 urologic pathologists.
  • Adenocarcinoma was identified in 19 biopsy cores corresponding to 16 (8.2%) patients and ASAP in 24 cores, corresponding to 19 patients (9.7%).
  • All missed prostate cancers were Gleason score 6 (3+3).
  • After correction for patient selection, the overall false-negative biopsy rate was estimated to be 2.4%; 1.1% for prostate cancer; and 1.3% for ASAP.
  • Clinicopathologic features at the time of initial biopsy and of subsequent prostate cancer diagnosis did not differ between patients with a false-negative or true benign biopsy.
  • Relatively low number of atypical glands (<10 glands), intense intermingling with preexistent glands or lack of architectural disorganization were the most prominent risk factors for a false-negative diagnosis.
  • Another potential pitfall was the presence of prostate cancer variants, as 1 adenocarcinoma was of foamy gland type and 3 of pseudohyperplastic type.
  • Routine examination of at least 1 level of prostate biopsy sets at high magnification and awareness of histologic prostate cancer variants might reduce the risk of missing or misinterpreting a relevant lesion at prostate biopsy evaluation.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Biopsy, Needle. Diagnostic Errors. Prostatic Neoplasms / pathology. Prostatic Neoplasms / surgery
  • [MeSH-minor] Aged. False Negative Reactions. Humans. Male. Middle Aged. Prostate-Specific Antigen / blood

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19935058.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


8. Waterman KC, MacDonald BC: Package selection for moisture protection for solid, oral drug products. J Pharm Sci; 2010 Nov;99(11):4437-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This time-based RH is calculationally combined with a moisture-sensitive Arrhenius equation (determined using the accelerated stability assessment program, ASAP) to predict the drug product's chemical stability over time as a function of storage conditions and packaging options.

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 Wiley-Liss, Inc. and the American Pharmacists Association
  • (PMID = 20845442.001).
  • [ISSN] 1520-6017
  • [Journal-full-title] Journal of pharmaceutical sciences
  • [ISO-abbreviation] J Pharm Sci
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down


9. Wesp W: Using STAT properly. Radiol Manage; 2006 Jan-Feb;28(1):26-30; quiz 31-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The diagnostic radiology department performed a 2-week analysis of orders in August 2004.
  • The manager, along with a staff radiologist, then created a list of clinical reasons that were appropriate for STAT, ASAP, or Routine orders.
  • These individuals then shared the list with their staff.
  • A second analysis conducted in November 2004 showed that an 11% decrease had been achieved.
  • With the success of this endeavor, the radiology department piloted a second program to further decrease the number of STAT orders.
  • The results showed that a STAT order could be completed and viewable on PACS in an average of 17 minutes, and an ASAP in 28 minutes.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16570491.001).
  • [ISSN] 0198-7097
  • [Journal-full-title] Radiology management
  • [ISO-abbreviation] Radiol Manage
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


10. Jiwa A, Kelly L, Pierre-Hansen N: Healing the community to heal the individual: literature review of aboriginal community-based alcohol and substance abuse programs. Can Fam Physician; 2008 Jul;54(7):1000-1000.e7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Healing the community to heal the individual: literature review of aboriginal community-based alcohol and substance abuse programs.
  • OBJECTIVE: To understand the development of culturally based and community-based alcohol and substance abuse treatment programs for aboriginal patients in an international context.
  • MeSH headings included the following: Indians, North American, Pacific ancestry group, aboriginal, substance-related disorders, alcoholism, addictive behaviour, community health service, and indigenous health.
  • The search produced 150 articles, 34 of which were relevant; most of the literature comprised opinion pieces and program descriptions (level III evidence).
  • MAIN MESSAGE: Substance abuse in some aboriginal communities is a complex problem requiring culturally appropriate, multidimensional approaches.
  • One promising perspective supports community-based programs or community mobile treatment.
  • These programs ideally cover prevention, harm reduction, treatment, and aftercare.
  • CONCLUSION: Community-based addictions programs are appropriate alternatives to treatment at distant residential addictions facilities.
  • The key components of success appear to be strong leadership in this area; strong community-member engagement; funding for programming and organizing; and the ability to develop infrastructure for longterm program sustainability.
  • Programs require increased documentation of their inroads in this developing field.
  • [MeSH-major] Alcoholism / ethnology. Alcoholism / rehabilitation. Substance-Related Disorders / ethnology. Substance-Related Disorders / rehabilitation

  • MedlinePlus Health Information. consumer health - Alcoholism and Alcohol Abuse.
  • MedlinePlus Health Information. consumer health - Drug Abuse.
  • MedlinePlus Health Information. consumer health - Opioid Abuse and Addiction.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Addiction. 2000 Jan;95(1):11-22 [10723822.001]
  • [Cites] Am J Med Qual. 2000 Jul-Aug;15(4):148-56 [10948787.001]
  • [Cites] Am Indian Alsk Native Ment Health Res. 2001;10(2):85-98 [11698985.001]
  • [Cites] J Psychoactive Drugs. 2003 Jan-Mar;35(1):15-25 [12733754.001]
  • [Cites] J Psychoactive Drugs. 2003 Jan-Mar;35(1):27-31 [12733755.001]
  • [Cites] J Psychoactive Drugs. 2003 Jan-Mar;35(1):71-7 [12733761.001]
  • [Cites] J Psychoactive Drugs. 2003 Jan-Mar;35(1):85-8 [12733763.001]
  • [Cites] J Psychoactive Drugs. 2003 Jan-Mar;35(1):89-96 [12733764.001]
  • [Cites] Alcohol Clin Exp Res. 2003 Aug;27(8):1356-60 [12966339.001]
  • [Cites] Am J Community Psychol. 2004 Jun;33(3-4):263-73 [15212184.001]
  • [Cites] Int J Addict. 1985 Nov-Dec;20(11-12):1707-26 [3833806.001]
  • [Cites] J Stud Alcohol. 1986 May;47(3):187-95 [3724152.001]
  • [Cites] Can J Public Health. 1988 Nov-Dec;79(6):424-9 [3233567.001]
  • [Cites] Community Health Stud. 1989;13(1):14-22 [2736901.001]
  • [Cites] R I Med J. 1991 Jun;74(6):281-6 [1887191.001]
  • [Cites] J Addict Dis. 1992;11(3):63-80 [1627667.001]
  • [Cites] Am Indian Alsk Native Ment Health Res. 1992;4(3):105-11; discussion 126-32 [1504169.001]
  • [Cites] Am Indian Alsk Native Ment Health Res. 1992;4(3):5-59; discussion 71-5, 95-100 [1504172.001]
  • [Cites] Int J Soc Psychiatry. 1992 Autumn;38(3):208-14 [1428664.001]
  • [Cites] Arctic Med Res. 1991;Suppl:271-5 [1365127.001]
  • [Cites] Aust J Public Health. 1995 Dec;19(6):567-72 [8616196.001]
  • [Cites] J Subst Abuse Treat. 1996 Jan-Feb;13(1):23-31 [8699539.001]
  • [Cites] J Subst Abuse Treat. 1996 May-Jun;13(3):265-71 [9017570.001]
  • [Cites] Subst Use Misuse. 1998 Nov;33(13):2605-46 [9818991.001]
  • [Cites] N Z Med J. 2006;119(1228):U1809 [16462919.001]
  • [CommentIn] Can Fam Physician. 2008 Jul;54(7):961, 963 [18625806.001]
  • (PMID = 18625824.001).
  • [ISSN] 1715-5258
  • [Journal-full-title] Canadian family physician Médecin de famille canadien
  • [ISO-abbreviation] Can Fam Physician
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Canada
  • [Number-of-references] 40
  • [Other-IDs] NLM/ PMC2464791
  •  go-up   go-down


11. Claassen G, Brin E, Crogan-Grundy C, Vaillancourt MT, Zhang HZ, Cai SX, Drewe J, Tseng B, Kasibhatla S: Selective activation of apoptosis by a novel set of 4-aryl-3-(3-aryl-1-oxo-2-propenyl)-2(1H)-quinolinones through a Myc-dependent pathway. Cancer Lett; 2009 Feb 18;274(2):243-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In order to identify pharmacological agents that cause selective apoptosis in tumors with deregulated Myc expression, we designed a cell-based screening assay based on our Anti-cancer Screening Apoptosis Program (ASAP) technology targeting increased activity in a "Myc-addicted" cancer cell panel.
  • [MeSH-minor] Caspases / metabolism. Cell Cycle. Cell Line, Tumor. Down-Regulation. Enzyme Activation. Humans. Magnetic Resonance Spectroscopy. Mass Spectrometry. Polymerase Chain Reaction. RNA Interference. RNA, Small Interfering. Ubiquitination

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19008038.001).
  • [ISSN] 1872-7980
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Quinolones; 0 / RNA, Small Interfering; EC 3.4.22.- / Caspases
  •  go-up   go-down


12. Karakiewicz PI, Perrotte P, McCormack M, Peloquin F, Perreault JP, Arjane P, Widmer H, Saad F: Early detection of prostate cancer with ultrasound-guided systematic needle biopsy. Can J Urol; 2005 Jun;12 Suppl 2:5-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early detection of prostate cancer with ultrasound-guided systematic needle biopsy.
  • INTRODUCTION: Prostate biopsy strategies have greatly evolved over the past 2 decades.
  • In the era of extended biopsy schemes, high-grade prostatic intraepithelial neoplasia no longer represents an independent predictor of prostate cancer on repeat biopsy.
  • Conversely, the risk is appreciably increased with atypical small acinar proliferation, and its presence warrants a repeat biopsy, which may be performed as soon as the pathologic findings of the previous biopsy become available.
  • CONCLUSION: Biopsy strategies and pathologic predictors of an increased risk of prostate cancer have appreciably changed over the past 2 decades.
  • [MeSH-major] Prostatic Neoplasms / pathology. Prostatic Neoplasms / ultrasonography

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16018825.001).
  • [ISSN] 1195-9479
  • [Journal-full-title] The Canadian journal of urology
  • [ISO-abbreviation] Can J Urol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Canada
  • [Number-of-references] 28
  •  go-up   go-down


13. Schlesinger C, Bostwick DG, Iczkowski KA: High-grade prostatic intraepithelial neoplasia and atypical small acinar proliferation: predictive value for cancer in current practice. Am J Surg Pathol; 2005 Sep;29(9):1201-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-grade prostatic intraepithelial neoplasia and atypical small acinar proliferation: predictive value for cancer in current practice.
  • In earlier studies, prostate cancer (PCa) has been reported to appear in 21% to 48% of subsequent biopsies for isolated high-grade prostatic intraepithelial neoplasia (PIN) and in 34% to 60% for isolated atypical small acinar proliferation suspicious for, but not diagnostic of, malignancy (ASAP).
  • The study group consisted of 336 men with initial diagnoses of PIN (n = 204), ASAP (n = 78), or both lesions (n = 54) who underwent at least one repeat biopsy.
  • Mean follow-up intervals in months were 6.0 for PIN, 3.8 for ASAP, and 4.9 for PIN/ASAP.
  • The predictive value of ASAP was significantly higher than that for PIN (P = 0.0188).
  • In 13 ASAP studies, mean PCa detection on follow-up was 45% until 1996 and 39% from 1997 to present.
  • PIN/ASAP predicted PCa in 33% of cases in our study, similar to ASAP alone (P = 0.65) and had a mean predictive value of 44% in the literature.
  • 1) extended biopsy techniques that yield higher rates of initial cancer detection, 2) lower detection rate for the remaining small cancers that may accompany PIN, and 3) remaining PIN cases may lack concomitant cancer.
  • [MeSH-major] Precancerous Conditions / diagnosis. Prostatic Intraepithelial Neoplasia / diagnosis. Prostatic Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Am J Surg Pathol. 2005 Nov;29(11):1548
  • (PMID = 16096410.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


1
Advertisement
4. Flannery RB Jr: Crisis intervention services and empirical data: lessons learned from the Assaulted Staff Action Program (ASAP). Int J Emerg Ment Health; 2008;10(4):271-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Crisis intervention services and empirical data: lessons learned from the Assaulted Staff Action Program (ASAP).
  • This paper reviews the lessons learned from the Assaulted Staff Action Program (ASAP) data base to illustrate how empirical data can meet the national standard of evidence-based care and improve the quality of services provided.
  • The ASAP data have demonstrated the safety and efficacy of ASAP as well as providing insights for risk management strategies in the changing face of patient violence.
  • [MeSH-major] Crisis Intervention. Empirical Research. Program Development. Violence

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19278143.001).
  • [ISSN] 1522-4821
  • [Journal-full-title] International journal of emergency mental health
  • [ISO-abbreviation] Int J Emerg Ment Health
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Italian Panel on Prostate Biopsy: [Consensus-based guidelines on prostate biopsy]. Arch Ital Urol Androl; 2005 Sep;77(3 Suppl 1):1-2, preceding 1
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Consensus-based guidelines on prostate biopsy].
  • OBJECTIVE: To develop evidence-based and consensus-based guidelines, helping physicians to take decisions about diagnostic procedures for men wishing to undergo examination for detection of prostate cancer.
  • MATERIAL AND METHODS: A panel of multidisciplinary Italian experts in urology, medical oncology, laboratory medicine, radiotherapy, pathology and methodologists for clinical trial (Mario Negri Institution) grouped together in 2002 to address specific questions relating to clinical controversies in prostate cancer diagnosis.
  • A practitioners feedback survey by means of a questionnaire of 49 items was also conducted in 2003 to assess the great variability in all the aspects relating a prostate biopsy (PB).
  • In the final document it has been reported as following: Prostatic biopsy (PB) is recommended in all patients with a PSA> = 4.0 ng/ml (2,5 ng/ml in patients with positive family history), abnormal DRE and %FPSA < 10%.
  • A PB should be repeated within 6-12 months in the following cases:1) First biopsy is inadequate (less than 6 cores, absence of prostatic cells on the cores), 2) in presence of HGPIN, ASAP or both on first PB, 3) in cases with persistently high levels of PSA (PSA > 10 ng/ml or PSA velocity > 0,75 ng/ml/year).

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16402723.001).
  • [ISSN] 1124-3562
  • [Journal-full-title] Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica
  • [ISO-abbreviation] Arch Ital Urol Androl
  • [Language] ITA
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


16. Brand TC, Thibault GP, Basler JW: Dealing with non-cancerous findings on prostate biopsy. Curr Urol Rep; 2006 May;7(3):186-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dealing with non-cancerous findings on prostate biopsy.
  • Most prostate biopsies do not show malignancy.
  • The proper management of non-cancerous pathologic findings of the prostate is controversial.
  • For this article, we reviewed the current literature for indications for repeat prostate biopsy after initial biopsies demonstrated non-cancerous prostatic tissue or benign prostatic hyperplasia.
  • This review includes discussions of management of asymptomatic prostatitis and how it may affect prostate-specific antigen, and also the management of several potentially premalignant lesions such as atrophy, atypical small acinar proliferation, and high-grade prostatic intraepithelial neoplasia.
  • [MeSH-major] Prostate / pathology. Prostatic Diseases / pathology
  • [MeSH-minor] Biopsy. Humans. Male. Prostatic Intraepithelial Neoplasia / pathology. Prostatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Prostate Diseases.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur Urol. 2005 Jan;47(1):38-44; discussion 44 [15582247.001]
  • [Cites] N Engl J Med. 1998 Oct 8;339(15):1036-42 [9761805.001]
  • [Cites] Eur Urol. 2000 Apr;37(4):404-12 [10765070.001]
  • [Cites] J Urol. 2004 Sep;172(3):906-8; discussion 908-9 [15310995.001]
  • [Cites] Scand J Urol Nephrol Suppl. 2000;(205):3-10 [11144902.001]
  • [Cites] BJU Int. 2003 Mar;91(4):350-4 [12603413.001]
  • [Cites] Urology. 2004 Mar;63(3):503-8 [15028446.001]
  • [Cites] CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30 [15661684.001]
  • [Cites] Am J Pathol. 2001 May;158(5):1767-73 [11337374.001]
  • [Cites] J Urol. 2000 Nov;164(5):1550-3 [11025702.001]
  • [Cites] Eur Urol. 2001 May;39(5):538-43 [11464034.001]
  • [Cites] Cleve Clin J Med. 2001 May;68(5):389-90, 392-3, 397 [11352318.001]
  • [Cites] Urology. 2005 Nov;66(5):1043-7 [16286121.001]
  • [Cites] J Urol. 2002 Apr;167(4):1723-6 [11912396.001]
  • [Cites] Urology. 2002 Jul;60(1):93-7 [12100931.001]
  • [Cites] J Urol. 1993 Mar;149(3):507-9 [7679753.001]
  • [Cites] Urology. 2004 Dec;64(6):1098-101 [15596176.001]
  • [Cites] J Urol. 1989 Jul;142(1):71-4; discussion 74-5 [2659827.001]
  • [Cites] J Reprod Fertil. 1970 Aug;22(3):573-4 [4989232.001]
  • [Cites] JAMA. 1984 Dec 21;252(23):3261-4 [6512929.001]
  • [Cites] J Urol. 2005 Jan;173(1):70-2 [15592031.001]
  • [Cites] Pathol Res Pract. 1995 Sep;191(9):838-41 [8606862.001]
  • [Cites] Arch Pathol Lab Med. 2003 Jul;127(7):840-4 [12823038.001]
  • [Cites] Urol Clin North Am. 2003 May;30(2):181-207 [12735497.001]
  • [Cites] BJU Int. 2004 Dec;94(9):1221-5 [15610093.001]
  • [Cites] BJU Int. 2004 Nov;94(7):963-4 [15541106.001]
  • [Cites] J Urol. 2003 Jan;169(1):12-9 [12478092.001]
  • [Cites] Urology. 2005 Apr;65(4):745-9 [15833520.001]
  • [Cites] Urology. 2000 Nov 1;56(5):828-32 [11068311.001]
  • [Cites] BJU Int. 2004 Dec;94(9):1239-44 [15610097.001]
  • [Cites] Curr Opin Urol. 2000 Jan;10(1):3-8 [10650506.001]
  • [Cites] Hum Pathol. 1999 Dec;30(12):1403-4 [10667415.001]
  • [Cites] Am J Pathol. 1999 Dec;155(6):1985-92 [10595928.001]
  • [Cites] Urology. 2004 Dec;64(6):1075-80 [15596172.001]
  • [Cites] J Urol. 1984 Oct;132(4):690-2 [6471214.001]
  • [Cites] Urology. 2005 Mar;65(3):538-42 [15780372.001]
  • [Cites] Urology. 2001 Dec;58(6):999-1003 [11744476.001]
  • [Cites] Urology. 2002 Nov;60(5):851-4 [12429314.001]
  • [Cites] J Urol. 2001 Aug;166(2):402-10 [11458037.001]
  • [Cites] Am J Surg Pathol. 2005 Sep;29(9):1201-7 [16096410.001]
  • [Cites] Urology. 1999 Apr;53(4):769-74 [10197854.001]
  • [Cites] J Natl Cancer Inst. 2005 Oct 5;97(19):1407-27 [16204691.001]
  • [Cites] J Urol. 1997 Apr;157(4):1301-3 [9120926.001]
  • [Cites] JAMA. 2005 Jul 6;294(1):66-70 [15998892.001]
  • [Cites] J Immunol. 1970 Jun;104(6):1329-39 [4986767.001]
  • [Cites] Public Health Rep. 2004 Mar-Apr;119(2):174-86 [15192905.001]
  • [Cites] World J Urol. 2003 Jun;21(2):105-8 [12687400.001]
  • (PMID = 16630522.001).
  • [ISSN] 1527-2737
  • [Journal-full-title] Current urology reports
  • [ISO-abbreviation] Curr Urol Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 47
  •  go-up   go-down


17. Feldman EM, Koshy JC, Chike-Obi CJ, Hatef DA, Bullocks JM, Stal S: Contemporary techniques in inferior turbinate reduction: survey results of the American Society for Aesthetic Plastic Surgery. Aesthet Surg J; 2010 Sep;30(5):672-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: A questionnaire was devised and sent to members of the American Society for Aesthetic Plastic Surgery (ASAPS) to determine their preferred methods for assessment and treatment of inferior turbinate hypertrophy.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20884896.001).
  • [ISSN] 1527-330X
  • [Journal-full-title] Aesthetic surgery journal
  • [ISO-abbreviation] Aesthet Surg J
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


18. Messieha Z, Ananda RC, Hoffman I, Hoffman W: Five year outcomes study of dental rehabilitation conducted under general anesthesia for special needs patients. Anesth Prog; 2007;54(4):170-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We assessed the safety of general anesthesia for dental treatment of special needs patients as it related to American Society of Anesthesiology Physical Status (ASAPS) classification, procedure, and other factors.
  • All records were evaluated by an independent evaluator who tabulated the patients' age, gender, ASAPS, and duration of procedure.
  • N = 363, age mean = 46.93 +/- 16.835 years, age median = 48 years, male patients = 180, female patients = 183, ASAPS I =183, ASAPS II = 127, ASAPS III = 53, duration of surgery mean = 140.631 +/- 23.104 minutes, duration of surgery median time = 142.000 minutes, and number of complications = 2.
  • One complication resulted in an ASAPS I 16-year-old boy, which was airway related, and a second was an ASAPS III 22-year-old woman, which was surgically related.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 1999 Nov 27;354(9193):1864-6 [10584723.001]
  • [Cites] Spec Care Dentist. 2006 Jan-Feb;26(1):25-9 [16703931.001]
  • [Cites] Eur J Anaesthesiol. 2000 Apr;17(4):230-5 [10866005.001]
  • [Cites] Spec Care Dentist. 2000 May-Jun;20(3):81-92 [11203886.001]
  • [Cites] Anaesthesia. 2001 Aug;56(8):745-55 [11493237.001]
  • [Cites] Paediatr Anaesth. 2001 Nov;11(6):637-41 [11696137.001]
  • [Cites] Drugs Aging. 2002;19(6):429-51 [12149050.001]
  • [Cites] Dent Clin North Am. 1987 Jan;31(1):131-8 [3468008.001]
  • [Cites] Anesth Pain Control Dent. 1992 Winter;1(1):46-8 [1392682.001]
  • [Cites] Anaesthesia. 1997 May;52(5):477-82 [9165968.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1997 Jun;83(6):646-51 [9195616.001]
  • [Cites] Lancet. 1998 Mar 21;351(9106):857-61 [9525362.001]
  • [Cites] Dent Clin North Am. 1999 Apr;43(2):301-19, vi [10331145.001]
  • [Cites] Minerva Anestesiol. 1999 Jul-Aug;65(7-8):499-505 [10479836.001]
  • [Cites] Drugs. 1999 Sep;58(3):453-67 [10493273.001]
  • [Cites] Anaesthesia. 2000 Jan;55(1):32-41 [10594431.001]
  • (PMID = 18085838.001).
  • [ISSN] 0003-3006
  • [Journal-full-title] Anesthesia progress
  • [ISO-abbreviation] Anesth Prog
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2213248
  •  go-up   go-down


19. Ploussard G, Plennevaux G, Allory Y, Salomon L, Azoulay S, Vordos D, Hoznek A, Abbou CC, de la Taille A: High-grade prostatic intraepithelial neoplasia and atypical small acinar proliferation on initial 21-core extended biopsy scheme: incidence and implications for patient care and surveillance. World J Urol; 2009 Oct;27(5):587-92
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-grade prostatic intraepithelial neoplasia and atypical small acinar proliferation on initial 21-core extended biopsy scheme: incidence and implications for patient care and surveillance.
  • PURPOSE: To evaluate the incidence of high-grade prostatic intraepithelial neoplasia (HGPIN) and atypical small acinar proliferation (ASAP) in an initial 21-core extended biopsy scheme and to determine the prostate cancer detection rate in the repeated biopsy.
  • Incidences of cancer, ASAP and HGPIN were studied.
  • Cancer detection rate in the repeated 21-core extended biopsy for ASAP and HGPIN was reported and compared with those obtained on repeated biopsy for clinico-biological indications.
  • RESULTS: Incidences of HGPIN and ASAP were 1.7 and 1.1%, respectively.
  • Seven prostate cancers were found among the 17 re-biopsies for ASAP revealing a detection rate of 41.2% (p = 0.01).
  • CONCLUSION: Our report demonstrates the different risk profiles for HGPIN and ASAP in a 21-core extended biopsy scheme.
  • Repeated biopsy is warranted when ASAP is diagnosed because of a high risk of prostate cancer.
  • [MeSH-major] Prostatic Intraepithelial Neoplasia / pathology. Prostatic Neoplasms / pathology


20. Lucignani G: How early? ASAP: molecular and functional imaging! Eur J Nucl Med Mol Imaging; 2007 Apr;34(4):596-601
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] How early? ASAP: molecular and functional imaging!

  • MedlinePlus Health Information. consumer health - Nuclear Scans.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nucl Med Commun. 2007 Jan;28(1):15-20 [17159544.001]
  • [Cites] N Engl J Med. 2006 Dec 21;355(25):2652-63 [17182990.001]
  • [Cites] Cancer Immunol Immunother. 2007 Aug;56(8):1163-71 [17171356.001]
  • [Cites] FASEB J. 2007 Feb;21(2):378-83 [17202248.001]
  • [Cites] Brain. 2006 Nov;129(Pt 11):2908-22 [17012294.001]
  • [Cites] N Engl J Med. 2006 Feb 2;354(5):496-507 [16452561.001]
  • [Cites] Clin Cancer Res. 2006 Oct 1;12 (19):5608-10 [17020961.001]
  • [Cites] Clin Cancer Res. 2006 Oct 1;12 (19):5659-67 [17020967.001]
  • [Cites] J Nucl Med. 2006 Nov;47(11):1778-86 [17079810.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Nov 1;66(3):845-51 [17011456.001]
  • [Cites] J Clin Oncol. 2006 Dec 1;24(34):5366-72 [17088570.001]
  • [Cites] Cancer. 2006 Dec 1;107(11):2678-87 [17063502.001]
  • [Cites] J Am Coll Cardiol. 2006 Dec 19;48(12 ):2448-57 [17174181.001]
  • (PMID = 17308918.001).
  • [ISSN] 1619-7070
  • [Journal-full-title] European journal of nuclear medicine and molecular imaging
  • [ISO-abbreviation] Eur. J. Nucl. Med. Mol. Imaging
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Radioisotopes; 0 / Radiopharmaceuticals
  • [Number-of-references] 14
  •  go-up   go-down


21. May DE, Kratochvil CJ, Puumala SE, Silva SG, Rezac AJ, Hallin MJ, Reinecke MA, Vitiello B, Weller EB, Pathak S, Simons AD, March JS: A manual-based intervention to address clinical crises and retain patients in the Treatment of Adolescents With Depression Study (TADS). J Am Acad Child Adolesc Psychiatry; 2007 May;46(5):573-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHOD: The use of adjunct services for attrition prevention (ASAP) is described for adolescents (ages 12-17 years) during the 12-week acute treatment in TADS, from 2000 to 2003.
  • RESULTS: Of 439 enrolled participants, 17.8% (n = 78) used ASAP primarily for suicidality or worsening of depression.
  • ASAP use did not differ between treatments (p =.97) and typically occurred early in treatment.
  • At the end of the 12 weeks, 37.2% of participants using ASAP remained in their assigned treatment, although 80.8% continued participating in assessments.
  • ASAP was associated with, at baseline, a higher severity of depression (p <.01), substance use (p <.01), and precontemplation level of change (p <.02).
  • CONCLUSIONS: ASAP may be useful to retain adolescent participants and as a safety intervention in placebo-controlled trials.
  • In clinical practice ASAP-like procedures may be useful to encourage adherence in patients engaging in long-term treatment.

  • Genetic Alliance. consumer health - Depression.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17450048.001).
  • [ISSN] 0890-8567
  • [Journal-full-title] Journal of the American Academy of Child and Adolescent Psychiatry
  • [ISO-abbreviation] J Am Acad Child Adolesc Psychiatry
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00006286
  • [Grant] United States / NIMH NIH HHS / MH / N01 MH80008
  • [Publication-type] Clinical Trial; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


22. Brewer BR, Pradhan S, Carvell G, Delitto A: Application of modified regression techniques to a quantitative assessment for the motor signs of Parkinson's disease. IEEE Trans Neural Syst Rehabil Eng; 2009 Dec;17(6):568-75
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We have used commercially available sensors to create a protocol called Advanced Sensing for Assessment of Parkinson's disease (ASAP) to obtain a quantitative and reliable measure of motor impairment in early to moderate PD.
  • The ASAP protocol measures grip force as an individual tracks a sinusoidal or pseudorandom target force under three conditions of increasing cognitive load.
  • Thirty individuals with PD have completed the ASAP protocol.
  • The ASAP data for 26 of these individuals were summarized in terms of 36 variables, and modified regression techniques were used to predict an individual's score on the Unified Parkinson Disease Rating Scale based on ASAP data.
  • These results demonstrate that the ASAP protocol can measure differences for individuals who are clinically different.
  • This indicates that the ASAP protocol may be able to measure changes with time in the motor signs of an individual with PD.
  • [MeSH-minor] Data Interpretation, Statistical. Humans. Regression Analysis. Reproducibility of Results. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Movement Disorders.
  • MedlinePlus Health Information. consumer health - Parkinson's Disease.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19884100.001).
  • [ISSN] 1558-0210
  • [Journal-full-title] IEEE transactions on neural systems and rehabilitation engineering : a publication of the IEEE Engineering in Medicine and Biology Society
  • [ISO-abbreviation] IEEE Trans Neural Syst Rehabil Eng
  • [Language] eng
  • [Grant] United States / NIA NIH HHS / AG / P30 AG024827
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS538314; NLM/ PMC4894031
  •  go-up   go-down


23. Robinson K, Creed J, Reguly B, Powell C, Wittock R, Klein D, Maggrah A, Klotz L, Parr RL, Dakubo GD: Accurate prediction of repeat prostate biopsy outcomes by a mitochondrial DNA deletion assay. Prostate Cancer Prostatic Dis; 2010 Jun;13(2):126-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Accurate prediction of repeat prostate biopsy outcomes by a mitochondrial DNA deletion assay.
  • We previously provided evidence that one of these deletions has potential utility in resolving false from true-negative prostate needle biopsies.
  • Using an empirically established cycle threshold (Ct) cutoff of 31, and the lowest Ct for each patient as diagnostic of prostate cancer, as well as the histopathologic diagnosis on second biopsy, we calculated the clinical performance of the deletion.
  • The results suggest that the majority of men with atypical small acinar proliferation have a concurrent missed tumor and therefore require close monitoring for early detection.
  • [MeSH-major] Biopsy, Needle. DNA, Mitochondrial / genetics. Prostatic Neoplasms / diagnosis. Sequence Deletion
  • [MeSH-minor] False Negative Reactions. Humans. Male. Middle Aged. Polymerase Chain Reaction. Prostate / pathology

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20084081.001).
  • [ISSN] 1476-5608
  • [Journal-full-title] Prostate cancer and prostatic diseases
  • [ISO-abbreviation] Prostate Cancer Prostatic Dis.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Mitochondrial
  •  go-up   go-down


24. van der Post L, Schoevers R, Koppelmans V, Visch I, Bernardt C, Mulder N, Beekman A, de Haan L, Dekker J: The Amsterdam Studies of Acute Psychiatry I (ASAP-I); a prospective cohort study of determinants and outcome of coercive versus voluntary treatment interventions in a metropolitan area. BMC Psychiatry; 2008;8:35
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The Amsterdam Studies of Acute Psychiatry I (ASAP-I); a prospective cohort study of determinants and outcome of coercive versus voluntary treatment interventions in a metropolitan area.
  • The number of studies that have examined this development and possible consequences in terms of optimizing health care delivery in emergency psychiatry is small and have a number of methodological shortcomings.
  • METHODS/DESIGN: This paper describes the design of the Amsterdam Study of Acute Psychiatry-I (ASAP-I).
  • The final aim is to find specific patient and health care factors that can be influenced by adjusting treatment programs in order to reduce the number of involuntary admissions.

  • MedlinePlus Health Information. consumer health - Psychotic Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Psychiatry Suppl. 2000;(39):s41-8 [10945077.001]
  • [Cites] Psychiatr Q. 2005 Summer;76(2):139-65 [15884742.001]
  • [Cites] Cochrane Database Syst Rev. 2002;(2):CD000011 [12076376.001]
  • [Cites] Soc Psychiatry Psychiatr Epidemiol. 2002 Jul;37(7):341-5 [12111027.001]
  • [Cites] J Clin Psychiatry. 2002 Oct;63(10):892-909 [12416599.001]
  • [Cites] Br J Psychiatry. 2003 Feb;182:105-16 [12562737.001]
  • [Cites] Br J Psychiatry. 2003 Feb;182:123-8 [12562739.001]
  • [Cites] Psychiatr Serv. 2003 Mar;54(3):351-5 [12610243.001]
  • [Cites] Soc Psychiatry Psychiatr Epidemiol. 2003 Sep;38(9):535-8 [14504739.001]
  • [Cites] J Clin Psychiatry. 2003;64 Suppl 16:24-33 [14680416.001]
  • [Cites] Br J Psychiatry. 2004 Feb;184:163-8 [14754830.001]
  • [Cites] Lancet. 2004 Jun 19;363(9426):2012-3 [15207948.001]
  • [Cites] Aust N Z J Psychiatry. 1976 Mar;10(1):27-32 [1065311.001]
  • [Cites] J Consult Clin Psychol. 1978 Jun;46(3):478-88 [670491.001]
  • [Cites] Psychol Med. 1983 Feb;13(1):177-83 [6133297.001]
  • [Cites] Psychol Med. 1985 Feb;15(1):189-94 [3991833.001]
  • [Cites] Arch Gen Psychiatry. 2005 Sep;62(9):975-83 [16143729.001]
  • [Cites] Am J Psychiatry. 2005 Oct;162(10):1785-804 [16199825.001]
  • [Cites] Ned Tijdschr Geneeskd. 2006 Feb 11;150(6):319-22 [16503024.001]
  • [Cites] Br J Psychiatry. 2006 Apr;188:386-91 [16582067.001]
  • [Cites] Psychiatr Prax. 2006 May;33(4):157-9 [16680625.001]
  • [Cites] Med Care. 1986 Jan;24(1):67-74 [3945130.001]
  • [Cites] Acta Psychiatr Scand. 1990 Jul;82(1):77-81 [2399824.001]
  • [Cites] J Pers Soc Psychol. 1990 Dec;59(6):1216-29 [2283588.001]
  • [Cites] Clin Neuropharmacol. 1991;14 Suppl 2:S33-44 [1684309.001]
  • [Cites] J Pers. 1992 Jun;60(2):175-215 [1635039.001]
  • [Cites] Acta Psychiatr Scand. 1992 Jul;86(1):32-7 [1414396.001]
  • [Cites] J Clin Psychiatry. 1993 Mar;54 Suppl:24-30 [8097195.001]
  • [Cites] Acta Psychiatr Scand. 1994 Jan;89(1):62-7 [7908156.001]
  • [Cites] Arch Gen Psychiatry. 1995 Mar;52(3):173-88 [7872841.001]
  • [Cites] Psychiatr Serv. 1996 May;47(5):487-96 [8740489.001]
  • [Cites] Lancet. 1996 Aug 10;348(9024):383-6 [8709739.001]
  • [Cites] Int Psychogeriatr. 1995 Fall;7(3):407-16 [8821348.001]
  • [Cites] Am J Psychiatry. 2005 Jan;162(1):12-24 [15625195.001]
  • [Cites] J Clin Pharm Ther. 2001 Oct;26(5):331-42 [11679023.001]
  • (PMID = 18479518.001).
  • [ISSN] 1471-244X
  • [Journal-full-title] BMC psychiatry
  • [ISO-abbreviation] BMC Psychiatry
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2413231
  •  go-up   go-down


25. Enerly E, Sheng Z, Li KB: Natural antisense as potential regulator of alternative initiation, splicing and termination. In Silico Biol; 2005;5(4):367-77
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Our analyses are based on the ASAP splicing annotation database from UCLA, the antisense transcripts data from Yelin et al., 2003, and the H-invitational full-length cDNA database from JBIRC, Japan.
  • [MeSH-minor] Databases, Genetic. Humans. Molecular Sequence Data. Sequence Analysis, RNA

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16268781.001).
  • [ISSN] 1386-6338
  • [Journal-full-title] In silico biology
  • [ISO-abbreviation] In Silico Biol. (Gedrukt)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / RNA, Antisense
  •  go-up   go-down


26. Martens MB, Keller JH: Routine immunohistochemical staining for high-molecular weight cytokeratin 34-beta and alpha-methylacyl CoA racemase (P504S) in postirradiation prostate biopsies. Mod Pathol; 2006 Feb;19(2):287-90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Routine immunohistochemical staining for high-molecular weight cytokeratin 34-beta and alpha-methylacyl CoA racemase (P504S) in postirradiation prostate biopsies.
  • A total of 43 cases of postirradiation prostate cores were assessed in an attempt to determine if routine use of alpha-methylacyl-CoA racemase (AMACR) in conjunction with high-molecular weight cytokeratin (HMWCK) would increase the recognition of carcinoma in postirradiation prostate biopsies.
  • We concluded that in most cases the addition of AMACR in conjunction with HMWCK does not increase the recognition of prostatic adenocarcinoma, however it is supportive in nature.
  • In one case the use of AMACR highlighted the extent of the adenocarcinoma which otherwise would have been designated as atypical small acinar proliferation (ASAP).
  • Further evaluation is required to assess the significance of a diagnosis of atypical small acinar proliferation in postirradiation prostate biopsies.
  • [MeSH-major] Keratins / analysis. Prostate / chemistry. Prostatic Neoplasms / metabolism. Racemases and Epimerases / analysis

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16341144.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 68238-35-7 / Keratins; EC 5.1.- / Racemases and Epimerases; EC 5.1.99.4 / alpha-methylacyl-CoA racemase
  •  go-up   go-down


27. Kuroda N, Katto K, Tamura M, Shiotsu T, Nakamura S, Ohtsuki Y, Hes O, Michal M, Inoue K, Ohara M, Mizuno K, Lee GH: Immunohistochemical application of D2-40 as basal cell marker in evaluating atypical small acinar proliferation of initial routine prostatic needle biopsy materials. Med Mol Morphol; 2010 Sep;43(3):165-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical application of D2-40 as basal cell marker in evaluating atypical small acinar proliferation of initial routine prostatic needle biopsy materials.
  • D2-40 has been recently discovered as a lymphatic endothelial cell marker, and some investigators have found that D2-40 is also expressed in myoepithelial cells of salivary gland or breast.
  • In this study, we evaluated D2-40 expression of basal cells and applied D2-40 immunohistochemistry in the combination of P504S, cytokeratin 5, and p63 for ten lesions with atypical small acinar proliferation (ASAP) in initial prostatic needle biopsy.
  • As a result, D2-40 was expressed in basal cells, lymphatic endothelial cells, and some stromal fibroblasts of normal prostatic tissue.
  • Among ten ASAP lesions, the final diagnosis of seven lesions was resolved by combination immunohistochemistry.
  • However, we found some D2-40-positive stromal fibroblasts or D2-40-positive lumen-collapsed lymphatic vessels neighboring atypical glands.
  • In conclusion, the combination of immunohistochemistry of P504S, cytokeratin 5, p63, and D2-40 may contribute to the accurate diagnosis of ASAP in the initial prostatic needle biopsy.
  • [MeSH-major] Antibodies, Monoclonal / analysis. Biomarkers, Tumor / analysis. Carcinoma, Acinar Cell / diagnosis. Prostatic Neoplasms / diagnosis
  • [MeSH-minor] Aged. Aged, 80 and over. Antibodies, Monoclonal, Murine-Derived. Biopsy, Needle. Early Diagnosis. Humans. Immunohistochemistry. Keratin-5 / isolation & purification. Male. Membrane Proteins / isolation & purification. Middle Aged. Prostate / pathology. Racemases and Epimerases / isolation & purification. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2004 Jul;28(7):946-52 [15223967.001]
  • [Cites] J Urol. 2004 Sep;172(3):906-8; discussion 908-9 [15310995.001]
  • [Cites] BJU Int. 2001 Jan;87(1):70-4 [11201402.001]
  • [Cites] Ann Diagn Pathol. 2006 Aug;10(4):205-8 [16844561.001]
  • [Cites] Am J Surg Pathol. 1999 Aug;23(8):925-31 [10435562.001]
  • [Cites] Med Mol Morphol. 2008 Jun;41(2):109-12 [18592165.001]
  • [Cites] Oral Oncol. 2006 Nov;42(10):1011-6 [16757205.001]
  • [Cites] Arch Pathol Lab Med. 2004 May;128(5):557-60 [15086303.001]
  • [Cites] Am J Surg Pathol. 2005 Nov;29(11):1435-41 [16224209.001]
  • [Cites] Am J Surg Pathol. 1997 Dec;21(12):1489-95 [9414193.001]
  • [Cites] Mod Pathol. 2006 Feb;19(2):287-90 [16341144.001]
  • [Cites] Histopathology. 2007 Nov;51(5):719-21 [17927601.001]
  • [Cites] BJU Int. 2007 Jan;99(1):49-52 [17227491.001]
  • [Cites] Am J Surg Pathol. 2002 Sep;26(9):1169-74 [12218573.001]
  • [Cites] Am J Surg Pathol. 2002 Sep;26(9):1161-8 [12218572.001]
  • [Cites] J Urol. 2005 Jan;173(1):70-2 [15592031.001]
  • [Cites] Mod Pathol. 2002 Apr;15(4):434-40 [11950918.001]
  • [Cites] Arch Pathol Lab Med. 2006 Jul;130(7):952-7 [16831049.001]
  • [Cites] Arch Pathol Lab Med. 2002 May;126(5):554-61 [11958660.001]
  • [Cites] Arch Pathol Lab Med. 2006 Jun;130(6):835-43 [16740037.001]
  • [Cites] Am J Surg Pathol. 1998 Nov;22(11):1430-1 [9808137.001]
  • [Cites] Hum Pathol. 2008 Feb;39(2):175-83 [18206495.001]
  • [Cites] Mod Pathol. 2004 Oct;17(10):1180-90 [15205683.001]
  • [Cites] J Urol. 2001 Sep;166(3):866-70 [11490235.001]
  • [Cites] Am J Surg Pathol. 2005 Sep;29(9):1201-7 [16096410.001]
  • [Cites] Am J Clin Pathol. 2000 Dec;114(6):896-909 [11338479.001]
  • [Cites] Histopathology. 2005 Jul;47(1):1-16 [15982318.001]
  • [Cites] Mod Pathol. 2006 Feb;19(2):180-5 [16341152.001]
  • [Cites] Am J Clin Pathol. 2004 Oct;122(4):517-23 [15487448.001]
  • (PMID = 20857265.001).
  • [ISSN] 1860-1499
  • [Journal-full-title] Medical molecular morphology
  • [ISO-abbreviation] Med Mol Morphol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Biomarkers, Tumor; 0 / CKAP4 protein, human; 0 / Keratin-5; 0 / Membrane Proteins; 0 / monoclonal antibody D2-40; EC 5.1.- / Racemases and Epimerases; EC 5.1.99.4 / alpha-methylacyl-CoA racemase
  •  go-up   go-down


28. Scattoni V, Roscigno M, Freschi M, Briganti A, Fantini GV, Bertini R, Salonia A, Montorsi F, Rigatti P: Predictors of prostate cancer after initial diagnosis of atypical small acinar proliferation at 10 to 12 core biopsies. Urology; 2005 Nov;66(5):1043-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predictors of prostate cancer after initial diagnosis of atypical small acinar proliferation at 10 to 12 core biopsies.
  • OBJECTIVES: To evaluate the factors that predict prostate cancer detection by means of 10 to 12 core repeat biopsies in patients with atypical small acinar proliferation (ASAP) results on initial biopsy.
  • METHODS: From 1998 to 2004, 110 of 127 patients (87%) with a diagnosis of ASAP were rebiopsied with the same technique plus additional biopsies on the ASAP site (12.6 +/- 1.1 cores [mean +/- standard deviation]).
  • RESULTS: On initial biopsy, a concomitant high-grade prostatic intraepithelial neoplasia (HGPIN) was present in 26 patients (23%) with ASAP.
  • The overall cancer detection rate was significantly higher in patients who had ASAP associated with HGPIN (58%), compared with patients who had isolated ASAP (35%; P = 0.04).
  • In the group of patients who had isolated ASAP, the rate of cancer detection was significantly higher in patients who had a prostatic volume less than 50 mL (56%) than in patients with a prostatic volume of 50 mL or more (27%; P = 0.03).
  • CONCLUSIONS: The cancer detection rate was significantly higher in patients with an ASAP associated with HGPIN on initial biopsy than in patients with isolated ASAP.
  • In ASAP patients, the detection rate was lower for patients with a larger prostate than in those with a smaller prostate.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma, Acinar Cell / pathology. Prostatic Intraepithelial Neoplasia / pathology. Prostatic Neoplasms / pathology

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16286121.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


29. Shearer AE, DeLuca AP, Hildebrand MS, Taylor KR, Gurrola J 2nd, Scherer S, Scheetz TE, Smith RJ: Comprehensive genetic testing for hereditary hearing loss using massively parallel sequencing. Proc Natl Acad Sci U S A; 2010 Dec 07;107(49):21104-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Sequencing reads were mapped using GSMAPPER, BFAST, and BOWTIE, and pathogenic variants were identified using a custom-variant calling and annotation pipeline (ASAP) that incorporates publicly available in silico pathogenicity prediction tools (SIFT, BLOSUM, Polyphen2, and Align-GVGD).
  • [MeSH-major] Genetic Testing / methods. Hearing Loss / genetics. Sequence Analysis, DNA / methods
  • [MeSH-minor] DNA Mutational Analysis. Genotype. Humans. Polymorphism, Single Nucleotide. Software

  • Genetic Alliance. consumer health - Hereditary hearing loss.
  • MedlinePlus Health Information. consumer health - Genetic Testing.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Hum Genet. 1997 Apr;60(4):758-64 [9106521.001]
  • [Cites] PLoS One. 2010;5(7):e11804 [20668687.001]
  • [Cites] Lancet. 2005 Mar 5-11;365(9462):879-90 [15752533.001]
  • [Cites] Orphanet J Rare Dis. 2006;1:40 [17032466.001]
  • [Cites] J Med Genet. 2007 Apr;44(4):233-40 [17098888.001]
  • [Cites] Hum Mutat. 1999;14(6):493-501 [10571947.001]
  • [Cites] J Med Genet. 2000 Jan;37(1):41-3 [10633133.001]
  • [Cites] Nucleic Acids Res. 1989 Oct 25;17(20):8390 [2813076.001]
  • [Cites] Ann N Y Acad Sci. 1991;630:16-31 [1952587.001]
  • [Cites] Hum Mutat. 2007 Jul;28(7):683-93 [17370310.001]
  • [Cites] Mol Ther. 2008 Feb;16(2):224-36 [18223547.001]
  • [Cites] Eur J Hum Genet. 2008 May;16(5):593-602 [18212818.001]
  • [Cites] Hum Mutat. 2008 Jun;29(6):E37-46 [18429043.001]
  • [Cites] Genet Med. 2008 Nov;10(11):797-804 [18941426.001]
  • [Cites] Am J Med Genet A. 2009 Feb;149A(2):280-5 [19161137.001]
  • [Cites] Nat Biotechnol. 2009 Feb;27(2):182-9 [19182786.001]
  • [Cites] Mutat Res. 2009 Mar-Jun;681(2-3):189-96 [18804553.001]
  • [Cites] Genome Biol. 2009;10(3):R32 [19327155.001]
  • [Cites] Nature. 2009 Sep 10;461(7261):272-6 [19684571.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Nov 10;106(45):19096-101 [19861545.001]
  • [Cites] Genome Biol. 2009;10(10):R116 [19835619.001]
  • [Cites] Nat Rev Genet. 2010 Jan;11(1):31-46 [19997069.001]
  • [Cites] Nat Genet. 2010 Jan;42(1):30-5 [19915526.001]
  • [Cites] BMC Genomics. 2009;10:646 [20043857.001]
  • [Cites] Nat Methods. 2010 Feb;7(2):111-8 [20111037.001]
  • [Cites] BMC Biotechnol. 2010;10:10 [20146813.001]
  • [Cites] Hum Mutat. 2010 Apr;31(4):484-91 [20127978.001]
  • [Cites] N Engl J Med. 2010 Apr 1;362(13):1181-91 [20220177.001]
  • [Cites] JAMA. 1999 Jun 16;281(23):2211-6 [10376574.001]
  • (PMID = 21078986.001).
  • [ISSN] 1091-6490
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] eng
  • [Grant] United States / NIDCD NIH HHS / DC / R01 DC002842; United States / NIDCD NIH HHS / DC / R01 DC003544; United States / NIGMS NIH HHS / GM / T32 GM082729; United States / NIDCD NIH HHS / DC / R01 DC02842
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3000272
  •  go-up   go-down


30. Dickinson SI: Premalignant and malignant prostate lesions: pathologic review. Cancer Control; 2010 Oct;17(4):214-22
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Premalignant and malignant prostate lesions: pathologic review.
  • BACKGROUND: High-grade prostatic intraepithelial neoplasia (HGPIN) is currently the only recognized premalignant lesion of prostatic carcinoma.
  • METHODS: This review article discusses HGPIN, its link to prostatic adenocarcinoma, and the significance of its presence on needle biopsy.
  • The criteria and clinical impact of the diagnosis of atypical small acinar proliferation on needle biopsy are reviewed.
  • Certain subtypes of prostate cancer that are not associated with HGPIN are of clinical relevance, and the unique clinicopathologic features of these subtypes are discussed.
  • Histologic variants of prostatic adenocarcinoma with distinct cell types are also described.
  • CONCLUSIONS: HGPIN has a strong association with acinar-type prostatic adenocarcinoma.
  • HGPIN and acinar-type prostatic adenocarcinoma both show similar molecular alterations, providing further evidence of their association.
  • [MeSH-major] Adenocarcinoma / pathology. Prostatic Intraepithelial Neoplasia / pathology. Prostatic Neoplasms / pathology
  • [MeSH-minor] Biopsy, Needle. Carcinoma, Acinar Cell / pathology. Humans. Male. Neoplasm Staging. Prognosis

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20861809.001).
  • [ISSN] 1526-2359
  • [Journal-full-title] Cancer control : journal of the Moffitt Cancer Center
  • [ISO-abbreviation] Cancer Control
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down


31. Elward AM, McAndrews JM, Young VL: Methicillin-sensitive and methicillin-resistant Staphylococcus aureus: preventing surgical site infections following plastic surgery. Aesthet Surg J; 2009 May-Jun;29(3):232-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • ASAPS members can complete this CME examination online by logging on to the ASAPS Members-Only Website (http://www.surgery.org/members) and clicking on "Clinical Education" in the menu bar.


32. Barton FE Jr: Aesthetic surgery of the face and neck. Aesthet Surg J; 2009 Nov-Dec;29(6):449-63; quiz 464-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • ASAPS members can complete this CME examination online by logging on to the ASAPS members-only website (http://www.surgery.org/members) and clicking on "Clinical Education" in the menu bar.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Aesthet Surg J. 2010 May;30(3):493
  • (PMID = 19944989.001).
  • [ISSN] 1527-330X
  • [Journal-full-title] Aesthetic surgery journal
  • [ISO-abbreviation] Aesthet Surg J
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


33. Merrick GS, Gutman S, Andreini H, Taubenslag W, Lindert DL, Curtis R, Adamovich E, Anderson R, Allen Z, Butler W, Wallner K: Prostate cancer distribution in patients diagnosed by transperineal template-guided saturation biopsy. Eur Urol; 2007 Sep;52(3):715-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prostate cancer distribution in patients diagnosed by transperineal template-guided saturation biopsy.
  • OBJECTIVES: To determine the prostate cancer incidence, anatomic distribution, Gleason score profile, and tumor burden in patients diagnosed by transperineal template-guided saturation biopsy (TTSB).
  • Criteria for inclusion included an elevated PSA and/or the diagnosis of ASAP or high-grade PIN on prior biopsy.
  • The prostate gland was divided into 24 regional biopsy locations.
  • Multiple clinical parameters were evaluated as predictors for prostate cancer diagnosis.
  • RESULTS: The mean patient age was 64.8 yr with a mean PSA of 9.1 ng/ml and a prostate volume of 78.6 cm(3).
  • Prostate cancer was diagnosed in 43 patients (42.2%) with a Gleason score distribution of 6-9.
  • No anatomic region of the prostate gland was spared of cancer.
  • In patients with prostate cancer, an average of 9.9 cores were involved.
  • In multivariate analysis, prostate volume was the best predictor for prostate cancer diagnosis.
  • CONCLUSIONS: TTBS diagnosed prostate cancer in 42.2% of patients.
  • Considerable anatomic variability in prostate cancer distribution was documented.
  • On the basis of this and other reports, cancer eradication will depend on treatment of the entire prostate gland.
  • [MeSH-major] Biopsy / methods. Carcinoma, Acinar Cell / epidemiology. Prostatic Neoplasms / epidemiology
  • [MeSH-minor] Aged. Biomarkers, Tumor / blood. Diagnosis, Differential. Humans. Incidence. Male. Middle Aged. Multivariate Analysis. Neoplasm Staging / methods. Perineum. Predictive Value of Tests. Prostate-Specific Antigen / blood. Retrospective Studies. United States / epidemiology


34. Newell KJ, Amrhein JF, Desai RJ, Middlebrook PF, Webster TM, Sawka BW, Rudrick BF: Prostate gland biopsies and prostatectomies: an Ontario community hospital experience. Can Urol Assoc J; 2008 Oct;2(5):518-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prostate gland biopsies and prostatectomies: an Ontario community hospital experience.
  • OBJECTIVE: Transrectal ultrasound-guided core biopsies of the prostate gland and prostatectomies have become common procedures at many community hospitals in Canada, especially in the era of serum prostate-specific antigen (PSA) screening for prostate cancer.
  • The Gleason grading of prostate cancer in biopsies and prostatectomies is a major determinant used for treatment planning.
  • There is evidence in the literature that suggests important discordance between community hospital pathologists and urological pathologists with respect to the Gleason grading of prostate cancer.
  • Our objective was to determine the diagnostic rates and Gleason scoring patterns for prostate gland biopsies and prostatectomies at our institution compared with the literature.
  • METHODS: We conducted a retrospective review of all prostate gland biopsies and prostatectomies performed at the Grey Bruce Health Services from January 2005 to September 2005.
  • The rates of diagnosis from prostate gland biopsies of benign (17.6%), high-grade prostatic intraepithelial neoplasia (11.0%), atypical small acinar proliferation suspicious for invasive malignancy (13.2%) and invasive prostatic adenocarcinoma (58.2%) at our institution were significantly different than those reported in the literature (p < 0.001).
  • CONCLUSION: Our results showed a significant difference in prostate gland biopsy categorical diagnoses compared with the literature.
  • There were also significant differences in categorical diagnoses of prostate gland biopsies among the community hospital pathologists in our study.
  • We would encourage other community hospital pathologists, in collaboration with their urologists, to review periodically their prostate gland pathology practices in an attempt to improve the uniformity of diagnoses.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Urol. 2007 Mar;177(3):903-6 [17296372.001]
  • [Cites] Cancer. 2000 Oct 15;89(8):1818-23 [11042578.001]
  • [Cites] Arch Pathol Lab Med. 2006 Jul;130(7):952-7 [16831049.001]
  • [Cites] Arch Pathol Lab Med. 2006 Jun;130(6):835-43 [16740037.001]
  • [Cites] Histopathology. 2006 May;48(6):655-62 [16681680.001]
  • [Cites] Histopathology. 2006 May;48(6):644-54 [16681679.001]
  • [Cites] J Urol. 2006 Mar;175(3 Pt 1):820-34 [16469560.001]
  • [Cites] Mod Pathol. 2006 Feb;19(2):180-5 [16341152.001]
  • [Cites] Am J Surg Pathol. 2005 Sep;29(9):1228-42 [16096414.001]
  • [Cites] Arch Pathol Lab Med. 2005 Aug;129(8):1004-10 [16048389.001]
  • [Cites] Mod Pathol. 2005 Feb;18(2):228-34 [15475927.001]
  • [Cites] Arch Pathol Lab Med. 1999 Aug;123(8):687-92 [10420224.001]
  • [Cites] Urology. 1998 Feb;51(2):186-95 [9495696.001]
  • [Cites] Am J Surg Pathol. 1997 May;21(5):566-76 [9158682.001]
  • [Cites] Am J Surg Pathol. 1996 Jul;20(7):851-7 [8669533.001]
  • [Cites] Arch Pathol Lab Med. 2003 Aug;127(8):1007-8 [12873176.001]
  • [Cites] Hum Pathol. 2001 Jan;32(1):81-8 [11172299.001]
  • [Cites] Hum Pathol. 2001 Jan;32(1):74-80 [11172298.001]
  • [Cites] J Urol. 2006 Sep;176(3):979-84; discussion 984 [16890675.001]
  • (PMID = 18953449.001).
  • [ISSN] 1911-6470
  • [Journal-full-title] Canadian Urological Association journal = Journal de l'Association des urologues du Canada
  • [ISO-abbreviation] Can Urol Assoc J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Other-IDs] NLM/ PMC2572237
  •  go-up   go-down


35. Lattouf JB, Grubb RL 3rd, Lee SJ, Bjurlin MA, Albert P, Singh AK, Ocak I, Choyke P, Coleman JA: Magnetic resonance imaging-directed transrectal ultrasonography-guided biopsies in patients at risk of prostate cancer. BJU Int; 2007 May;99(5):1041-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Magnetic resonance imaging-directed transrectal ultrasonography-guided biopsies in patients at risk of prostate cancer.
  • OBJECTIVE: To evaluate whether using endorectal-coil magnetic resonance imaging (erMRI) before transrectal ultrasonography (TRUS)-guided biopsies of the prostate increases the yield of cancer in a high-risk population, and in a subset analysis to compare the yield with high-field (3 T) vs lower field (1.5 T) MRI.
  • PATIENTS AND METHODS: Between March 2003 and November 2005, 26 consecutive patients had erMRI before their TRUS biopsy of the prostate (median age 62 years, range 32-76).
  • The median prostate-specific antigen (PSA) level was 8.40 (2.1-85.9) ng/mL.
  • All patients had at least one previous negative prostate biopsy (median 3, range 1-12).
  • Twenty-three patients had at least one risk factor for prostate cancer (family history, high PSA velocity, low percentage of free PSA, prostatic intraepithelial neoplasia or atypical small acinar proliferation on previous biopsy).
  • [MeSH-major] Magnetic Resonance Imaging / standards. Prostatic Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Biopsy, Needle / methods. Digital Rectal Examination / methods. Humans. Male. Middle Aged. Predictive Value of Tests. Prostate-Specific Antigen / metabolism. Risk Factors. Sensitivity and Specificity. Ultrasonography, Interventional


36. Ding J, Erdal S, Borlawsky T, Liu J, Golden-Kreutz D, Kamal J, Payne PR: The design of a pre-encounter clinical trial screening tool: ASAP. AMIA Annu Symp Proc; 2008 Nov 06;:931
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The design of a pre-encounter clinical trial screening tool: ASAP.
  • In order to increase the efficiency of such processes, we have developed a web-based system, called Advanced Screening for Active Protocols (ASAP).

  • MedlinePlus Health Information. consumer health - Clinical Trials.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18998826.001).
  • [ISSN] 1942-597X
  • [Journal-full-title] AMIA ... Annual Symposium proceedings. AMIA Symposium
  • [ISO-abbreviation] AMIA Annu Symp Proc
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / UL1 RR025755
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


37. Hu K, Berenjian S, Larsson R, Gullbo J, Nygren P, Lövgren T, Morein B: Nanoparticulate Quillaja saponin induces apoptosis in human leukemia cell lines with a high therapeutic index. Int J Nanomedicine; 2010;5:51-62
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Two fractions of QS were selected for particle formation, one with an acyl-chain (ASAP) was used to form killing and growth-inhibiting (KGI) particles, and the other without the acyl-chain (DSAP) was used to formulate blocking and balancing effect (BBE) particles.
  • The monoblastoid lymphoma cell line U937 was selected for analyzing the mode of action.

  • MedlinePlus Health Information. consumer health - Herbal Medicine.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Nutr. 1995 Mar;125(3 Suppl):717S-724S [7884557.001]
  • [Cites] Biochemistry. 1988 Nov 29;27(24):8861-9 [2853972.001]
  • [Cites] Vaccine. 2005 Mar 18;23(17-18):2331-5 [15755622.001]
  • [Cites] Trends Immunol. 2005 Jul;26(7):381-7 [15978523.001]
  • [Cites] Cancer Biol Ther. 2005 Aug;4(8):874-82 [16082187.001]
  • [Cites] Carcinogenesis. 2007 Jun;28(6):1347-55 [17148504.001]
  • [Cites] J Immunol. 1991 Jan 15;146(2):431-7 [1987271.001]
  • [Cites] Adv Drug Deliv Rev. 2001 Sep 23;51(1-3):149-59 [11516786.001]
  • [Cites] Toxicol Appl Pharmacol. 2002 Jun 15;181(3):192-202 [12079428.001]
  • [Cites] J Intern Med. 2003 Jan;253(1):46-75 [12588538.001]
  • [Cites] Curr Med Chem Anticancer Agents. 2004 May;4(3):263-72 [15134504.001]
  • [Cites] Mol Cancer Ther. 2004 May;3(5):521-6 [15141009.001]
  • [Cites] Cancer Res. 1970 Jun;30(6):1874-82 [4318708.001]
  • [Cites] Biochim Biophys Acta. 1976 Mar 26;424(3):469-80 [1259971.001]
  • [Cites] Cancer Res. 1991 Feb 1;51(3):995-1002 [1988143.001]
  • [Cites] Biochim Biophys Acta. 1991 Feb 25;1062(2):165-71 [2004105.001]
  • [Cites] Mol Immunol. 1991 Mar;28(3):285-6 [2017197.001]
  • [Cites] Int J Cancer. 1992 Jan 21;50(2):177-85 [1730510.001]
  • [Cites] Int J Cancer. 1994 Jul 15;58(2):269-74 [7913083.001]
  • [Cites] Nature. 1984 Mar 29-Apr 4;308(5958):457-60 [6709052.001]
  • [Cites] Cancer Res. 1986 Oct;46(10):5125-30 [2875788.001]
  • [Cites] Vaccine. 1995 Oct;13(14):1375-82 [8585296.001]
  • (PMID = 20161987.001).
  • [ISSN] 1178-2013
  • [Journal-full-title] International journal of nanomedicine
  • [ISO-abbreviation] Int J Nanomedicine
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Plant Extracts
  • [Other-IDs] NLM/ PMC2819906
  • [Keywords] NOTNLM ; Quillaja saponin / anticancer drug / apoptosis / nanoparticle
  •  go-up   go-down


38. Schiaffino E: The natural history: how has prostate cancer trend modified? Arch Ital Urol Androl; 2005 Jun;77(3):167-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The natural history: how has prostate cancer trend modified?
  • The patients' number submitted to prostate fine-needle biopsy has constantly increased in the last years, posing technical and diagnostic problems to the pathologist.
  • In other cases, when only a few atypical glands are present, a very cautious behaviour is the rule.
  • The acronym "ASAP" (atypical small acinar proliferation) has been suggested in such cases.

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16372513.001).
  • [ISSN] 1124-3562
  • [Journal-full-title] Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica
  • [ISO-abbreviation] Arch Ital Urol Androl
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


39. Pepe P, Aragona F: Prostate needle biopsy: 12 vs. 18 cores -- is it necessary? Urol Int; 2005;74(1):19-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prostate needle biopsy: 12 vs. 18 cores -- is it necessary?
  • INTRODUCTION: The aim of this study is to compare the histological results of a prostate needle biopsy scheme of 12 and 18 cores used in 372 consecutive patients submitted to an early stage diagnosis programme for prostate cancer (PCa).
  • MATERIALS AND METHODS: From February 2002 to July 2003 a transperineal TRUS-guided prostate needle biopsy was performed in 372 patients aged 40-73.
  • RESULTS: 159 (42.7%) patients were diagnosed with PCa, 138 (37%) with BPH, 58 (15.7%) with chronic prostatitis, 15 (4%) with a HGPIN, 2 (0.6%) with ASAP.
  • CONCLUSIONS: Extended schemes of prostate needle biopsy of 18 or more cores increases the PCa diagnosis in early stage and should be adopted for young patients with a PSA <10 ng/ml, negative DRE and in case of rebiopsies.
  • [MeSH-major] Biopsy, Needle / statistics & numerical data. Prostate / pathology. Prostatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15711103.001).
  • [ISSN] 0042-1138
  • [Journal-full-title] Urologia internationalis
  • [ISO-abbreviation] Urol. Int.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  •  go-up   go-down


40. Flannery RB Jr, Walker AP: Characteristics of patients in restraint: fifteen-year analysis of the Assaulted Staff Action Program (ASAP) with EMS implications. Int J Emerg Ment Health; 2008;10(3):191-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characteristics of patients in restraint: fifteen-year analysis of the Assaulted Staff Action Program (ASAP) with EMS implications.
  • This study compared restrained/nonrestrained subjects on the demographic, precipitant variables and added three clinical variables (past violence to others, personal victimization, and substance use disorder) to assess the possible predictive power of clinical variables.
  • [MeSH-major] Emergency Medical Services. Program Development. Psychotic Disorders / psychology. Restraint, Physical. Violence / psychology

  • MedlinePlus Health Information. consumer health - Emergency Medical Services.
  • MedlinePlus Health Information. consumer health - Psychotic Disorders.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19112931.001).
  • [ISSN] 1522-4821
  • [Journal-full-title] International journal of emergency mental health
  • [ISO-abbreviation] Int J Emerg Ment Health
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


41. Yanke BV, Salzhauer EW, Colon I: Is race a positive predictor of cancer on repeat prostate biopsy? J Urol; 2006 Sep;176(3):1114-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is race a positive predictor of cancer on repeat prostate biopsy?
  • PURPOSE: High grade intraepithelial neoplasia and atypical small acinar proliferation increase the probability of cancer on a subsequent prostate biopsy.
  • We investigated whether race is prognostic for detecting cancer in patients undergoing repeat prostate biopsies.
  • MATERIALS AND METHODS: At a single institution 416 men underwent 2 or more prostate biopsies from January 1993 through June 2003 for a total of 1,023 biopsies.
  • We retrospectively examined multiple factors, including patient age, race, total number of biopsy cores total number of previously negative biopsy cores, prostate specific antigen, prostate specific antigen slope, digital rectal examination and family history of prostate cancer.
  • Previous high grade intraepithelial neoplasia, atypical small acinar proliferation and Gleason score in positive biopsies were recorded from the histopathology review.
  • The Cox proportional hazards model was used for multivariate analysis.
  • When clinical and pathological variables were compared between the racial groups, black men had significantly higher prostate specific antigen (p = 0.02).
  • There was no statistically significant difference in patient age, total number of cores, number of previous negative cores, prostate specific antigen slope, abnormal digital rectal examination, family history, or previous high grade intraepithelial neoplasia or atypical small acinar proliferation.
  • Multivariate analysis showed that race approached but did not achieve statistical significance as a predictor of prostate cancer on repeat biopsy (p = 0.09).
  • Previous high grade intraepithelial neoplasia (p = 0.0025), previous atypical small acinar proliferation (p = 0.0049), digital rectal examination (p = 0.0076) and prostate specific antigen slope (p = 0.0005) were independent predictors of prostate cancer on repeat biopsy.
  • Of patients with previous atypical small acinar proliferation black men had a significantly higher rate of cancer detection on repeat biopsy.
  • CONCLUSIONS: Previous high grade intraepithelial neoplasia, atypical small acinar proliferation, digital rectal examination and prostate specific antigen slope were independent predictors of prostate cancer on repeat biopsy.
  • [MeSH-major] Biopsy, Needle / statistics & numerical data. Prostatic Neoplasms / ethnology. Prostatic Neoplasms / pathology

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16890704.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


42. Ahyai SA, Isbarn H, Karakiewicz PI, Chun FK, Reichert M, Walz J, Steuber T, Jeldres C, Schlomm T, Heinzer H, Salomon G, Budäus L, Perrotte P, Huland H, Graefen M, Haese A: The presence of prostate cancer on saturation biopsy can be accurately predicted. BJU Int; 2010 Mar;105(5):636-41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The presence of prostate cancer on saturation biopsy can be accurately predicted.
  • OBJECTIVE: To improve the ability of our previously reported saturation biopsy nomogram quantifying the risk of prostate cancer, as the use of office-based saturation biopsy has increased.
  • PATIENTS AND METHODS: Saturation biopsies of 540 men with one or more previously negative 6-12 core biopsies were used to develop a multivariable logistic regression model-based nomogram, predicting the probability of prostate cancer.
  • Candidate predictors were used in their original or stratified format, and consisted of age, total prostate-specific antigen (PSA) level, percentage free PSA (%fPSA), gland volume, findings on a digital rectal examination, cumulative number of previous biopsy sessions, presence of high-grade prostatic intraepithelial neoplasia on any previous biopsy, and presence of atypical small acinar proliferation (ASAP) on any previous biopsy.
  • RESULTS: Prostate cancer was diagnosed in 39.4% of saturation biopsies.
  • Age, total PSA, %fPSA, gland volume, number of previous biopsies, and presence of ASAP at any previous biopsy were independent predictors for prostate cancer (all P < 0.05).
  • The nomogram was 77.2% accurate and had a virtually perfect correlation between predicted and observed rates of prostate cancer.
  • CONCLUSIONS: We improved the accuracy of the saturation biopsy nomogram from 72% to 77%; it relies on three previously included variables, i.e. age, %fPSA and prostate volume, and on three previously excluded variables, i.e.
  • PSA, the number of previous biopsy sessions, and evidence of ASAP on previous biopsy.
  • [MeSH-major] Nomograms. Prostate / pathology. Prostatic Intraepithelial Neoplasia / pathology. Prostatic Neoplasms / pathology


43. Bialocerkowski A, Kurlowicz K, Vladusic S, Grimmer K: Effectiveness of primary conservative management for infants with obstetric brachial plexus palsy. Int J Evid Based Healthc; 2005 Mar;3(2):27-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Search strategy  A systematic literature search was performed using 14 databases: TRIP, MEDLINE, CINAHL, AMED, Web of Science, Proquest 5000, Evidence Based Medicine Reviews, Expanded Academic ASAP, Meditext, Science Direct, Physiotherapy Evidence Database, Proquest Digital Dissertations, Open Archives Initiative Search Engine, Australian Digital Thesis Program.
  • Data collection and analysis  Two independent reviewers assessed the eligibility of each study for inclusion into the review, the study design used and its methodological quality.

  • COS Scholar Universe. author profiles.
  • PubMed Health. DARE review .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21631743.001).
  • [ISSN] 1744-1595
  • [Journal-full-title] International journal of evidence-based healthcare
  • [ISO-abbreviation] Int J Evid Based Healthc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


44. Mearini L, Costantini E, Bellezza G, Cavaliere A, Zucchi A, Bini V, Porena M: Is there any clinical parameter able to predict prostate cancer after initial diagnosis of atypical small acinar proliferation? Urol Int; 2008;81(1):29-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is there any clinical parameter able to predict prostate cancer after initial diagnosis of atypical small acinar proliferation?
  • INTRODUCTION: Tissue samples from prostate biopsy may contain atypical small acinar proliferation (ASAP): present guidelines recommend a repeat biopsy policy.
  • MATERIALS AND METHODS: From 1999 to 2005, 1,274 patients underwent a prostate biopsy: in 5.9% ASAP was found, and patients underwent a second biopsy.
  • Uni- and multivariate analysis compared the clinical patterns of cancer patients with the no cancer group at second biopsy.
  • RESULTS: Univariate analysis showed significant differences in PSA ratio density, prostate volume, final PSA values and Delta PSA; at multivariate logistic regression analysis, only PSA ratio (OR = 0.743, 95% CI 0.620-0.891) and prostate volume (OR = 0.960, 95% CI 0.924-0.998) were predictive of malignancy.
  • CONCLUSIONS: In our experience, PSA ratio and prostate volume seem to be independent predictors of prostate cancer at re-biopsy.
  • [MeSH-major] Cell Proliferation. Prostatic Neoplasms / diagnosis. Prostatic Neoplasms / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Biopsy. Humans. Male. Medical Oncology / methods. Middle Aged. Multivariate Analysis. Predictive Value of Tests. Prostate-Specific Antigen / biosynthesis. ROC Curve. Regression Analysis. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 S. Karger AG, Basel.
  • (PMID = 18645268.001).
  • [ISSN] 1423-0399
  • [Journal-full-title] Urologia internationalis
  • [ISO-abbreviation] Urol. Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


45. Twohig M, Skilton SJ, Fujimoto G, Ellor N, Plumb RS: Rapid detection and identification of counterfeit and [corrected] adulterated products of synthetic phosphodiesterase type-5 inhibitors with an atmospheric solids analysis probe. Drug Test Anal; 2010 Feb;2(2):45-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rapid detection and identification of counterfeit and [corrected] adulterated products of synthetic phosphodiesterase type-5 inhibitors with an atmospheric solids analysis probe.
  • An Atmospheric Solids Analysis Probe (ASAP) was used for the direct analysis of the counterfeit pharmaceuticals and herbal products.
  • Using the ASAP combined with time-of-flight mass spectrometry (TOF MS) it was possible to detect fraudulent counterfeit tablets.
  • Detecting adulteration for five herbal supplements marketed as natural alternatives to PDE-5 inhibitors was also possible using the ASAP.

  • MedlinePlus Health Information. consumer health - Drug Safety.
  • Hazardous Substances Data Bank. SILDENAFIL .
  • Hazardous Substances Data Bank. TADALAFIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 John Wiley & Sons, Ltd.
  • [ErratumIn] Drug Test Anal. 2011 Mar;3(3):191-3
  • (PMID = 20878886.001).
  • [ISSN] 1942-7611
  • [Journal-full-title] Drug testing and analysis
  • [ISO-abbreviation] Drug Test Anal
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Carbolines; 0 / Counterfeit Drugs; 0 / Phosphodiesterase 5 Inhibitors; 0 / Piperazines; 0 / Plant Preparations; 0 / Purines; 0 / Sulfones; 742SXX0ICT / Tadalafil; BW9B0ZE037 / Sildenafil Citrate
  •  go-up   go-down


86. Dong J, Dai WD, Fang TL, Lin H, Uemura T: [Osteoblastic differentiation and in vivo osteogenic activity of marrow-derived mesenchymal stem cells stimulated by Tacrolimus: experiment with rats]. Zhonghua Yi Xue Za Zhi; 2007 Jan 16;87(3):190-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Some MSCs were cultured with L-ascorbic acid-2-phosphate (AsAP) and beta-glycerophosphate (beta-GP) or FK506 plus AsAP and beta-GP.
  • Multiparous beta-tricalcium phosphate (beta-TCP) ceramic cubes were dipped into 2 kinds of suspension of MSCs, treated by FK506 + AsAP + beta-GP or AsAP + beta-GP, so as to produce 48 pieces of MSCs/beta-TCP complex that were randomly divided into 2 equal groups to be cultured with AsAP + beta-GP or AsAP + beta-GP + FK506 for 4 weeks.
  • RESULTS: In vitro assays showed that the APase activity, calcium deposition, expression of osteocalcin mRNA of the FK506 + AsAP + beta-GP group at any time points were all significantly higher than those of the AsAP + beta-GP group (all P < 0.05).
  • SEM showed that since the 16th day after culture calcified nodules began to be seen in the FK506 + AsAP + beta-GP group.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17425851.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; 0 / RNA, Messenger; 104982-03-8 / Osteocalcin; EC 3.1.3.1 / Alkaline Phosphatase; WM0HAQ4WNM / Tacrolimus
  •  go-up   go-down


87. McFarland BH, Gabriel RM, Bigelow DA, Walker RD: Organization and financing of alcohol and substance abuse programs for American Indians and Alaska Natives. Am J Public Health; 2006 Aug;96(8):1469-77
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Organization and financing of alcohol and substance abuse programs for American Indians and Alaska Natives.
  • OBJECTIVES: Although American Indians and Alaska Natives have high rates of substance abuse, few data about treatment services for this population are available.
  • METHODS: Using data from the Indian Health Service (IHS), the Substance Abuse and Mental Health Services Administration, the National Institute on Alcohol Abuse and Alcoholism, the Henry J.
  • Kaiser Family Foundation, and the Census Bureau, we estimated the number of American Indians served by substance abuse treatment programs that apparently are unaffiliated with either the IHS or tribal governments.
  • RESULTS: Half of the American Indians and Alaska Natives treated for substance abuse were served by programs (chiefly in urban areas) apparently unaffiliated with the IHS or tribal governments.
  • IHS substance abuse expenditures were roughly what we expected.
  • Medicaid participation by tribal programs was not universal.
  • CONCLUSIONS: Many Native people with substance abuse problems are served by programs unaffiliated with the IHS.

  • MedlinePlus Health Information. consumer health - Drug Abuse.
  • MedlinePlus Health Information. consumer health - Drugs and Young People.
  • MedlinePlus Health Information. consumer health - Native American Health.
  • MedlinePlus Health Information. consumer health - Opioid Abuse and Addiction.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Drug Alcohol Depend. 2004 Jun 11;74(3):223-34 [15194200.001]
  • [Cites] Am J Public Health. 2004 Jan;94(1):53-9 [14713698.001]
  • [Cites] Am J Public Health. 2000 Mar;90(3):344-51 [10705850.001]
  • [Cites] Am J Med Qual. 2000 Jul-Aug;15(4):148-56 [10948787.001]
  • [Cites] J Addict Dis. 2000;19(3):13-34 [11076117.001]
  • [Cites] Am J Public Health. 2000 Nov;90(11):1720-3 [11076238.001]
  • [Cites] Psychiatr Serv. 2001 Jan;52(1):68-74 [11141531.001]
  • [Cites] J Psychoactive Drugs. 2002 Jan-Mar;34(1):1-6 [12003107.001]
  • [Cites] Psychiatr Serv. 2002 Jul;53(7):802 [12096160.001]
  • [Cites] J Addict Dis. 2003;22(2):15-29 [12703666.001]
  • [Cites] Alcohol Clin Exp Res. 2003 Aug;27(8):1333-6 [12966333.001]
  • [Cites] J Stud Alcohol Suppl. 1981 Jan;9:143-58 [7012345.001]
  • [Cites] Public Health Rep. 1988 Nov-Dec;103(6):611-20 [3141955.001]
  • [Cites] J Subst Abuse Treat. 1992;9(2):93-102 [1512807.001]
  • [Cites] West J Med. 1992 Sep;157(3):281-5 [1413770.001]
  • [Cites] Addiction. 1993 Mar;88(3):315-35 [8461850.001]
  • [Cites] Am J Health Promot. 1995 Mar-Apr;9(4):288-99 [10150732.001]
  • [Cites] J Subst Abuse. 1995;7(1):1-8 [7655307.001]
  • [Cites] J Subst Abuse. 1995;7(1):135-50 [7655309.001]
  • [Cites] J Subst Abuse. 1995;7(1):27-42 [7655310.001]
  • [Cites] Am Indian Alsk Native Ment Health Res. 1995;6(3):31-45 [8555352.001]
  • [Cites] J Stud Alcohol. 1995 Nov;56(6):597-610 [8558890.001]
  • [Cites] Lancet. 1996 Jan 27;347(8996):237-40 [8551886.001]
  • [Cites] J Clin Epidemiol. 1996 Apr;49(4):473-82 [8622000.001]
  • [Cites] JAMA. 1996 Jun 19;275(23):1786-8 [8642709.001]
  • [Cites] J Stud Alcohol. 1996 May;57(3):229-43 [8709580.001]
  • [Cites] J Stud Alcohol. 1996 Jan;57(1):65-72 [8747503.001]
  • [Cites] JAMA. 1997 Apr 2;277(13):1039-45 [9091691.001]
  • [Cites] JAMA. 1997 Apr 2;277(13):1079-80 [9091699.001]
  • [Cites] Adm Policy Ment Health. 1997 Jul;24(6):459-74 [9385711.001]
  • [Cites] Med Care Res Rev. 1997 Dec;54(4):490-507 [9437178.001]
  • [Cites] N Engl J Med. 1998 Feb 26;338(9):592-602 [9475768.001]
  • [Cites] Am J Public Health. 1998 Feb;88(2):193-5 [9491006.001]
  • [Cites] J Behav Health Serv Res. 1998 Nov;25(4):377-96 [9796161.001]
  • [Cites] Subst Use Misuse. 1998 Nov;33(13):2605-46 [9818991.001]
  • [Cites] J Subst Abuse Treat. 1999 Jan;16(1):71-80 [9888124.001]
  • [Cites] Am J Public Health. 2005 May;95(5):766-8 [15855449.001]
  • [Cites] J Behav Health Serv Res. 2000 Feb;27(1):17-28 [10695238.001]
  • (PMID = 16809606.001).
  • [ISSN] 1541-0048
  • [Journal-full-title] American journal of public health
  • [ISO-abbreviation] Am J Public Health
  • [Language] ENG
  • [Grant] United States / NIAAA NIH HHS / AA / R21 AA014050; United States / NIAAA NIH HHS / AA / 1R21 AA014050; United States / CSAP SAMHSA HHS / SP / 1U79 SP10346
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC1522117
  •  go-up   go-down


88. Sirisoma N, Pervin A, Drewe J, Tseng B, Cai SX: Discovery of substituted N'-(2-oxoindolin-3-ylidene)benzohydrazides as new apoptosis inducers using a cell- and caspase-based HTS assay. Bioorg Med Chem Lett; 2009 May 15;19(10):2710-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report the discovery of a series of substituted N'-(2-oxoindolin-3-ylidene)benzohydrazides as inducers of apoptosis using our proprietary cell- and caspase-based ASAP HTS assay.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19369076.001).
  • [ISSN] 1464-3405
  • [Journal-full-title] Bioorganic & medicinal chemistry letters
  • [ISO-abbreviation] Bioorg. Med. Chem. Lett.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Hydrazines; 0 / N'-(4-bromo-5-methyl-2-oxoindolin-3-ylidene)-3,4,5-trimethoxybenzohydrazide; 0 / Tubulin Modulators; EC 3.4.22.- / Caspases
  •  go-up   go-down


89. Kim KH, Kim YB, Lee JK, Kim YJ, Jung TY: Pathologic results of radical prostatectomies in patients with simultaneous atypical small acinar proliferation and prostate cancer. Korean J Urol; 2010 Jun;51(6):398-402
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pathologic results of radical prostatectomies in patients with simultaneous atypical small acinar proliferation and prostate cancer.
  • PURPOSE: The incidence of adenocarcinoma on a subsequent biopsy following a diagnosis of atypical small acinar proliferation (ASAP) ranges from 34% to 60%.
  • We reexamined radical prostatectomy (RP) specimens of patients diagnosed as having synchronous ASAP with prostate cancer (PCa) to evaluate pathological entities and the clinical significance of ASAP.
  • MATERIALS AND METHODS: From January 2007 to December 2008, a total of 118 patients who had been diagnosed with adenocarcinoma on prostate needle biopsy underwent RP.
  • Forty-six of the 118 patients (39%) were diagnosed as having synchronous ASAP with PCa on the prostate needle biopsy.
  • Using whole-mount sections and prostate mapping, we evaluated the RP specimens that were close sections to the ASAP on prostate needle biopsy.
  • RESULTS: Thirty-six of the 46 patients (78%) were diagnosed as having adenocarcinoma at sites of ASAP on the initial prostate needle biopsies.
  • CONCLUSIONS: Most ASAP on initial prostate needle biopsy was a true pathological entity, in other words, prostatic adenocarcinoma.
  • Aggressive approaches including more extended repeat biopsy with additional biopsy of the site of the ASAP are needed to diagnose PCa in patients with ASAP.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] World J Urol. 2009 Oct;27(5):587-92 [19373471.001]
  • [Cites] J Urol. 2001 May;165(5):1409-14 [11342887.001]
  • [Cites] Eur Urol. 2008 Dec;54(6):1306-13 [18083294.001]
  • [Cites] BJU Int. 2007 Apr;99(4):780-5 [17378841.001]
  • [Cites] BJU Int. 2007 Jan;99(1):49-52 [17227491.001]
  • [Cites] Eur Urol. 2006 Oct;50(4):666-74 [16930809.001]
  • [Cites] Arch Pathol Lab Med. 2006 Jun;130(6):835-43 [16740037.001]
  • [Cites] Anal Quant Cytol Histol. 2006 Apr;28(2):104-10 [16637513.001]
  • [Cites] Eur Urol. 2006 Jan;49(1):49-53; discussion 53 [16314035.001]
  • [Cites] Am J Surg Pathol. 2005 Sep;29(9):1201-7 [16096410.001]
  • [Cites] Int J Urol. 2005 Apr;12(4):353-60 [15948721.001]
  • [Cites] Am J Clin Pathol. 2005 Feb;123(2):231-6 [15842047.001]
  • [Cites] Urology. 1999 Feb;53(2):351-5 [9933053.001]
  • [Cites] Urology. 1998 May;51(5):749-57; discussion 757-8 [9610588.001]
  • [Cites] Virchows Arch. 1997 Jan;430(1):1-16 [9037309.001]
  • [Cites] Hum Pathol. 1993 Aug;24(8):819-32 [8375853.001]
  • [Cites] J Urol. 1989 Jul;142(1):71-4; discussion 74-5 [2659827.001]
  • [Cites] J Urol. 2004 Sep;172(3):906-8; discussion 908-9 [15310995.001]
  • [Cites] Arch Pathol Lab Med. 2004 May;128(5):557-60 [15086303.001]
  • [Cites] Am J Surg Pathol. 2004 Feb;28(2):239-43 [15043314.001]
  • [Cites] J Urol. 2003 Aug;170(2 Pt 1):370-2 [12853777.001]
  • [Cites] Int J Urol. 2003 Feb;10(2):68-71 [12588600.001]
  • [Cites] Urology. 2002 Nov;60(5):851-4 [12429314.001]
  • [Cites] J Urol. 2001 Aug;166(2):402-10 [11458037.001]
  • [Cites] BJU Int. 2001 Jul;88(2):147-57 [11446873.001]
  • [Cites] Urol Oncol. 2009 Sep-Oct;27(5):509-13 [18625570.001]
  • (PMID = 20577606.001).
  • [ISSN] 2005-6745
  • [Journal-full-title] Korean journal of urology
  • [ISO-abbreviation] Korean J Urol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2890056
  • [Keywords] NOTNLM ; Needle biopsy / Prostatectomy / Prostatic neoplasms / Surgical pathology
  •  go-up   go-down


90. Ray AD, Hammond J, Major H: Molecular ions and protonated molecules observed in the atmospheric solids analysis probe analysis of steroids. Eur J Mass Spectrom (Chichester); 2010;16(2):169-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular ions and protonated molecules observed in the atmospheric solids analysis probe analysis of steroids.
  • Atmospheric pressure chemical ionisation (APCI) has often been used to ionise steroids in mass spectrometry, usually when interfaced to high-performance liquid chromatography (HPLC).
  • The recently introduced technique of atmospheric solids analysis probe (ASAP) has the advantage that the sample can be analysed directly and does not need to be interfaced to HPLC.
  • Existing ionisation sources such as direct analysis in real time (DART) and desorption electrospray ionisation (DESI) have shown the advantage of direct analysis techniques in a variety of applications.
  • ASAP can be performed on commercial atmospheric pressure ionisation (API) mass spectrometers with only simple modifications to API sources.
  • A range of commercially available steroids were analysed by ASAP to investigate the mechanism of ionisation.
  • ASAP analysis of steroids generally results in the formation of the parent molecular ion as either the radical cation M+* or the protonated molecule MH+.
  • [MeSH-major] Atmospheric Pressure. Protons. Spectrometry, Mass, Electrospray Ionization / methods. Steroids / chemistry

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20212333.001).
  • [ISSN] 1469-0667
  • [Journal-full-title] European journal of mass spectrometry (Chichester, England)
  • [ISO-abbreviation] Eur J Mass Spectrom (Chichester)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Protons; 0 / Steroids
  •  go-up   go-down


91. Bravo LC, Asian Strategic Alliance for Pneumococcal Disease Prevention (ASAP) Working Group: Overview of the disease burden of invasive pneumococcal disease in Asia. Vaccine; 2009 Dec 9;27(52):7282-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This paper represents a collaborative effort by the Asian Strategic Alliance for Pneumococcal Disease Prevention (ASAP) Working Group to collate data on the disease burden due to invasive pneumococcal disease (IPD) in participating Asian countries and territories; namely, Hong Kong, India, Indonesia, Korea, Macau, Malaysia, Pakistan, the Philippines, Singapore, Sri Lanka, Taiwan and Thailand.
  • A review of both published and unpublished data revealed that the incidence of IPD in some countries is well documented by way of large, long-duration studies, while in other countries, much of the available data have been extrapolated from international studies or have come from small population studies of limited geographical coverage.

  • MedlinePlus Health Information. consumer health - Pneumococcal Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19393708.001).
  • [ISSN] 1873-2518
  • [Journal-full-title] Vaccine
  • [ISO-abbreviation] Vaccine
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 68
  • [Investigator] Chan CW; Lee KK; Lui KM; Shah N; Kukreja S; Kartasasmita C; Hadinegoro SR; Lee HJ; Nordin Mb; Yusoff NK; Ismail Z; Memon IA; Maqbool S; Bhutta ZA; Ong-Lim AL; Maramba CC; Chong CY; Goh DY; Lamabadusuriya SP; Chiu CH; Lee PI; Lolekha S; Thisyakorn U
  •  go-up   go-down


92. Samaratunga H, Gardiner RA, Yaxley J, Brown I: Atypical prostatic glandular proliferations on needle biopsy: Diagnostic implications, use of immunohistochemistry, and clinical significance. Anal Quant Cytol Histol; 2006 Apr;28(2):104-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Atypical prostatic glandular proliferations on needle biopsy: Diagnostic implications, use of immunohistochemistry, and clinical significance.
  • In recent times, PSA screening and a substantial increase in prostate needle biopsies have not only resulted in detection of minute foci of cancer but have also very likely resulted in increased detection of atypical glandular proliferations.
  • Not uncommonly, there are only a limited number of atypical glands in these biopsies, and these require careful evaluation to enable an accurate diagnosis.
  • Foci of atypical glands, also labeled atypical small acinar proliferation of uncertain significance, have features suspicious for but not diagnostic of cancer.
  • Atypical foci include a broad group of lesions of differing clinical significance.
  • These include benign, small acinar proliferations mimicking prostate cancer and atypical glandular proliferations suspicious for carcinoma.
  • Patients with atypical glands on prostate needle biopsy have a high risk for harboring cancer and therefore have an increased risk for having cancer detected in subsequent biopsies.

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16637513.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 35
  •  go-up   go-down


93. Paradela S, Martínez-Gómez W, Fernández-Jorge B, Castiñeiras I, Yebra-Pimentel T, Llinares P, Fonseca Capdevila E: Toxic epidermal necrolysis-like acute cutaneous lupus erythematosus. Lupus; 2007;16(9):741-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The term "Acute Syndrome of Apoptotic Pan-Epidermolysis" (ASAP) designs clinical entities characterized by massive cleavage of the epidermis resulting from hyperacute epidermal basal cell apoptotic injury.
  • Although most cases of ASAP in the setting of LE are drug-induced TEN, there are reported cases of "TEN-like" LE with subacute progression, absence of systemic involvement and lack of drug ingestion.


94. Luo R, Miller Jenkins LM, Randazzo PA, Gruschus J: Dynamic interaction between Arf GAP and PH domains of ASAP1 in the regulation of GAP activity. Cell Signal; 2008 Nov;20(11):1968-77
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • ASAP family Arf GAPs induce the hydrolysis of GTP bound to the Ras superfamily protein Arf1, regulate cell adhesion and migration and have been implicated in carcinogenesis.
  • The ASAP proteins have a core catalytic domain of PH, Arf GAP and Ank repeat domains.
  • Here, using NMR spectroscopy and biochemical analysis, we have further tested this hypothesis and characterized the interdomain interaction.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 2003 Jun 6;278(23):21099-104 [12657629.001]
  • [Cites] J Biol Chem. 2003 May 16;278(20):18393-400 [12637522.001]
  • [Cites] Dev Cell. 2003 Sep;5(3):513-21 [12967569.001]
  • [Cites] Cell Signal. 2004 Sep;16(9):1033-44 [15212764.001]
  • [Cites] EMBO J. 2004 Oct 13;23(20):3918-28 [15457207.001]
  • [Cites] Eur J Biochem. 1991 Dec 5;202(2):569-74 [1761056.001]
  • [Cites] J Biomol NMR. 1993 Mar;3(2):185-204 [8477186.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Jan 31;92(3):816-20 [7846058.001]
  • [Cites] J Biomol NMR. 1995 Nov;6(3):277-93 [8520220.001]
  • [Cites] Science. 1995 Dec 22;270(5244):1999-2002 [8533093.001]
  • [Cites] Structure. 1995 Nov 15;3(11):1185-95 [8591029.001]
  • [Cites] Cell. 1996 May 31;85(5):621-4 [8646770.001]
  • [Cites] Mol Cell Biol. 1998 Dec;18(12):7038-51 [9819391.001]
  • [Cites] J Magn Reson. 1999 Oct;140(2):451-9 [10497050.001]
  • [Cites] J Biol Chem. 2005 Mar 11;280(10):8884-92 [15632162.001]
  • [Cites] EMBO J. 2005 Mar 9;24(5):963-73 [15719014.001]
  • [Cites] Clin Cancer Res. 2005 May 15;11(10):3609-13 [15897555.001]
  • [Cites] Cell Signal. 2005 Oct;17(10):1276-88 [16038802.001]
  • [Cites] J Cell Sci. 2005 Aug 1;118(Pt 15):3555-66 [16079295.001]
  • [Cites] Curr Biol. 2005 Dec 6;15(23):2164-9 [16332543.001]
  • [Cites] Methods Enzymol. 2005;404:147-63 [16413266.001]
  • [Cites] Methods Enzymol. 2005;404:164-74 [16413267.001]
  • [Cites] Curr Biol. 2006 Jan 24;16(2):130-9 [16431365.001]
  • [Cites] J Cell Sci. 2006 Apr 1;119(Pt 7):1203-11 [16554436.001]
  • [Cites] J Biomol NMR. 2006;36 Suppl 1:21 [16642402.001]
  • [Cites] Biochemistry. 2006 Dec 26;45(51):15301-9 [17176052.001]
  • [Cites] Biochem J. 2007 Mar 15;402(3):439-47 [17112341.001]
  • [Cites] J Biol Chem. 2007 Apr 13;282(15):11356-64 [17277311.001]
  • [Cites] EMBO J. 2007 Jul 25;26(14):3484-93 [17581628.001]
  • [Cites] Biol Cell. 2007 Oct;99(10):583-600 [17868031.001]
  • [Cites] Traffic. 2007 Nov;8(11):1465-75 [17666108.001]
  • [Cites] Traffic. 2007 Nov;8(11):1644-55 [17760859.001]
  • [Cites] Mol Cell Biol. 2007 Dec;27(23):8271-83 [17893324.001]
  • [Cites] J Biol Chem. 1994 Apr 8;269(14):10758-63 [8144664.001]
  • [Cites] EMBO J. 1999 Dec 15;18(24):6890-8 [10601011.001]
  • [Cites] J Biol Chem. 2000 Mar 31;275(13):9653-63 [10734117.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Apr 11;97(8):4011-6 [10725410.001]
  • [Cites] Methods Enzymol. 2001;329:343-54 [11210554.001]
  • [Cites] EMBO J. 2002 Mar 15;21(6):1315-26 [11889037.001]
  • [Cites] FEBS Lett. 2002 Feb 20;513(1):71-6 [11911883.001]
  • [Cites] Mol Biol Cell. 2002 Jun;13(6):2147-56 [12058076.001]
  • [Cites] Genome Res. 2002 Nov;12(11):1625-41 [12421749.001]
  • [Cites] J Struct Biol. 2003 Jan;141(1):63-76 [12576021.001]
  • [Cites] Traffic. 2003 Apr;4(4):201-13 [12694559.001]
  • [Cites] Curr Opin Cell Biol. 2003 Aug;15(4):396-404 [12892779.001]
  • (PMID = 18675341.001).
  • [ISSN] 0898-6568
  • [Journal-full-title] Cellular signalling
  • [ISO-abbreviation] Cell. Signal.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z01 BC007365-13; United States / Intramural NIH HHS / / Z99 CA999999
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / GTPase-Activating Proteins; 0 / Inositol Phosphates; 0 / Lipid Bilayers; 0 / Phosphatidylinositol 4,5-Diphosphate; 0 / Phospholipids; EC 3.6.5.2 / ADP-Ribosylation Factors
  • [Other-IDs] NLM/ NIHMS58368; NLM/ PMC2574850
  •  go-up   go-down


95. Lum PS, Mulroy S, Amdur RL, Requejo P, Prilutsky BI, Dromerick AW: Gains in upper extremity function after stroke via recovery or compensation: Potential differential effects on amount of real-world limb use. Top Stroke Rehabil; 2009 Jul-Aug;16(4):237-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Therefore, amount of arm use may depend critically on the location, extent, and type of functional gains, which can be quantified with comprehensive kinematic and EMG analysis of ADL performance.
  • A new treatment approach called Accelerated Skill Acquisition Program (ASAP) focuses on impairment reduction coupled with repetitive, task-specific training of the paretic arm during ADLs.
  • We present pilot data that show recovery in subjects who received the ASAP, while a usual care control subject showed increased use of compensation over the same period.
  • Finally, we discuss the advantages of data reduction methods such as principal components analysis, confirmatory factor analysis, and structural equation modeling, which can potentially distill large kinematic and EMG data sets into the key latent variables that predict amount of real-world use.

  • MedlinePlus Health Information. consumer health - Stroke.
  • MedlinePlus Health Information. consumer health - Stroke Rehabilitation.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19740730.001).
  • [ISSN] 1074-9357
  • [Journal-full-title] Topics in stroke rehabilitation
  • [ISO-abbreviation] Top Stroke Rehabil
  • [Language] eng
  • [Publication-type] Controlled Clinical Trial; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


96. Singh KK, Erkelenz S, Rattay S, Dehof AK, Hildebrandt A, Schulze-Osthoff K, Schaal H, Schwerk C: Human SAP18 mediates assembly of a splicing regulatory multiprotein complex via its ubiquitin-like fold. RNA; 2010 Dec;16(12):2442-54
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RNPS1, Acinus, and SAP18 form the apoptosis- and splicing-associated protein (ASAP) complex, which is also part of the exon junction complex.
  • Here we have investigated splicing regulatory activities of the ASAP components.
  • Detailed mutational analysis and three-dimensional modeling data revealed that the ubiquitin-like fold of SAP18 was required for efficient splicing regulatory activity.

  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] RNA. 2000 Sep;6(9):1197-211 [10999598.001]
  • [Cites] Mol Cell Biol. 2008 Apr;28(8):2549-58 [18250153.001]
  • [Cites] RNA. 2001 Mar;7(3):421-34 [11333022.001]
  • [Cites] Nature. 2002 Jul 11;418(6894):236-43 [12110900.001]
  • [Cites] Genome Res. 2002 Aug;12(8):1231-45 [12176931.001]
  • [Cites] Nature. 2002 Sep 12;419(6903):182-5 [12226669.001]
  • [Cites] Annu Rev Genet. 2002;36:333-60 [12429696.001]
  • [Cites] Mol Cell Biol. 2003 Apr;23(8):2981-90 [12665594.001]
  • [Cites] Mol Cell. 2003 Jul;12(1):5-14 [12887888.001]
  • [Cites] Nat Biotechnol. 2003 Aug;21(8):921-6 [12872131.001]
  • [Cites] Nat Rev Mol Cell Biol. 2003 Aug;4(8):605-12 [12923522.001]
  • [Cites] Annu Rev Biochem. 2003;72:291-336 [12626338.001]
  • [Cites] Mol Cell Biol. 2004 Feb;24(3):1174-87 [14729963.001]
  • [Cites] J Virol. 2004 Jun;78(12):6517-26 [15163745.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jun 8;101(23):8551-6 [15161980.001]
  • [Cites] Prog Nucleic Acid Res Mol Biol. 2004;78:37-88 [15210328.001]
  • [Cites] Mol Biol Cell. 2004 Aug;15(8):3876-90 [15169873.001]
  • [Cites] Mol Cell Biol. 1986 Sep;6(9):3173-9 [3023965.001]
  • [Cites] Biochemistry. 1987 Dec 15;26(25):8221-7 [3327519.001]
  • [Cites] EMBO J. 1993 Feb;12(2):595-600 [8440248.001]
  • [Cites] EMBO J. 1994 Dec 1;13(23):5679-88 [7988565.001]
  • [Cites] Genes Dev. 1996 Jul 1;10(13):1569-79 [8682289.001]
  • [Cites] Curr Protoc Bioinformatics. 2006 Oct;Chapter 5:Unit 5.6 [18428767.001]
  • [Cites] Nat Struct Mol Biol. 2008 May;15(5):444-51 [18425143.001]
  • [Cites] Genes Dev. 2010 Jun 1;24(11):1073-4 [20516191.001]
  • [Cites] J Virol. 1997 Apr;71(4):2757-64 [9060629.001]
  • [Cites] Cell. 1997 May 2;89(3):357-64 [9150135.001]
  • [Cites] Nucleic Acids Res. 1998 Mar 1;26(5):1345-51 [9469847.001]
  • [Cites] J Cell Sci. 1998 Jun;111 ( Pt 11):1495-506 [9580558.001]
  • [Cites] EMBO J. 1999 Aug 16;18(16):4560-70 [10449421.001]
  • [Cites] Nature. 1999 Sep 9;401(6749):168-73 [10490026.001]
  • [Cites] Curr Biol. 2004 Dec 29;14(24):2283-8 [15620657.001]
  • [Cites] Mol Cell Biol. 2005 Feb;25(4):1446-57 [15684395.001]
  • [Cites] Trends Biochem Sci. 2005 Mar;30(3):115-8 [15752982.001]
  • [Cites] J Biol Chem. 2005 Jun 17;280(24):22641-50 [15837790.001]
  • [Cites] Mol Cell. 2005 Jul 1;19(1):1-13 [15989960.001]
  • [Cites] EMBO J. 2005 Oct 19;24(20):3543-54 [16177823.001]
  • [Cites] RNA. 2005 Dec;11(12):1869-83 [16314458.001]
  • [Cites] J Mol Biol. 2006 Jan 27;355(4):821-44 [16310215.001]
  • [Cites] RNA. 2006 Feb;12(2):292-302 [16428608.001]
  • [Cites] Bioinformatics. 2006 Feb 1;22(3):365-6 [16332707.001]
  • [Cites] BMC Struct Biol. 2006;6:1 [16396680.001]
  • [Cites] J Comput Aided Mol Des. 2005 Nov;19(11):791-800 [16470421.001]
  • [Cites] J Biol Chem. 2006 May 5;281(18):12475-84 [16537548.001]
  • [Cites] Genes Dev. 2006 Jul 1;20(13):1755-65 [16766678.001]
  • [Cites] Biochemistry. 2006 Oct 3;45(39):11974-82 [17002296.001]
  • [Cites] Protein Sci. 2006 Nov;15(11):2507-24 [17075131.001]
  • [Cites] Biochim Biophys Acta. 2008 Feb;1780(2):214-25 [18022399.001]
  • [Cites] Nucleic Acids Res. 2008 Mar;36(5):1450-63 [18203748.001]
  • [Cites] Bioinformatics. 2000 Sep;16(9):815-24 [11108704.001]
  • (PMID = 20966198.001).
  • [ISSN] 1469-9001
  • [Journal-full-title] RNA (New York, N.Y.)
  • [ISO-abbreviation] RNA
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carrier Proteins; 0 / Multiprotein Complexes; 0 / RNPS1 protein, human; 0 / Ribonucleoproteins; 0 / SAP18 protein, human; 0 / Ubiquitin
  • [Other-IDs] NLM/ PMC2995405
  •  go-up   go-down


97. Pascual Mateo C, Luján Galán M, Rodríguez García N, Llanes González L, Berenguer Sánchez A: [Clinical significance of prostatic intraepithelial neoplasm and atypical small acinar proliferation: relationship with prostate cancer]. Actas Urol Esp; 2008 Jul-Aug;32(7):680-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical significance of prostatic intraepithelial neoplasm and atypical small acinar proliferation: relationship with prostate cancer].
  • [Transliterated title] Significado clínico de la neoplasia intraepitelial prostática y de la proliferación acinar focal atípica: relación con el cáncer de próstata.
  • INTRODUCTION: Prostatic intraepithelial neoplasia (PIN) and atypical small acinar proliferation (ASAP) in the setting of prostatic needle biopsies are considered premalignant although questions still remain.
  • MATERIAL AND METHODS: We collected 138 subjects (108 PIN, 30 ASAP); in 67% we performed a second biopsy and the rate of cancer in this late biopsy were 19% and 27% respectively.
  • We cannot identify any clinical factor to predict the finding of cancer in the re-biopsy (PSA, age, digital rectal examination, prostatic volume).
  • RESULTS: In the follow-up, we observed higher rates of cancer for the ASAP; the finding of ASAP was the single clinical or histopathological factor that was an independent predictor of cancer.
  • CONCLUSIONS: We observed that the finding of ASAP was an indication for re-biopsy because of the higher rates of cancer; on the contrary, the paper of PIN in the prostatic needle biopsy still requires further investigation.
  • [MeSH-major] Prostatic Intraepithelial Neoplasia / pathology. Prostatic Neoplasms / pathology
  • [MeSH-minor] Biopsy. Cell Proliferation. Humans. Male. Middle Aged. Retrospective Studies


98. Pereira TC, Clayton AC, Tazelaar HD, Liu Y, Leon M, Silverman JF: Critical values in cytology. Diagn Cytopathol; 2006 Jun;34(6):447-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • (1) no phone call necessary, (2) phone call within 24 hr, (3) phone call as soon as possible (ASAP).
  • Most respondents agreed on the need for a phone call ASAP in many situations, and important additional CV cases were suggested.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16680772.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


99. Flannery RB Jr, Walker AP, Flannery GJ: Elderly patient assaults: empirical data from the Assaulted Staff Action Program (ASAP) with risk management implications for EMS personnel. Int J Emerg Ment Health; 2006;8(4):221-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Elderly patient assaults: empirical data from the Assaulted Staff Action Program (ASAP) with risk management implications for EMS personnel.
  • Data on the assault characteristics of elderly patients are presented from a 15-year, retrospective, longitudinal study of the Assaulted Staff Action Program (ASAP).


100. Mansilha CR, Coelho CA, Reinas A, Moutinho A, Ferreira S, Pizarro C, Tavares A: Salmonella: the forgotten pathogen: health hazards of compliance with European bathing water legislation. Mar Pollut Bull; 2010 Jun;60(6):819-26
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Attending the high prevalence of Salmonella found (23.1%) it seemed important to improve the efficiency of the conventional analytical method (ISO 6340:1995), comparing its draft with SML-VIDAS Salmonella and two new chromogenic media: AES Salmonella Agar Plate (ASAP) and Simple Method Salmonella (SMS).
  • ASAP showed the higher efficiency and can be recommended for a faster detection and presumptive identification of salmonellae in bathing waters.

  • MedlinePlus Health Information. consumer health - Water Pollution.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20152993.001).
  • [ISSN] 1879-3363
  • [Journal-full-title] Marine pollution bulletin
  • [ISO-abbreviation] Mar. Pollut. Bull.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Chromogenic Compounds
  •  go-up   go-down






Advertisement